WO2013036994A1 - Composés pour le traitement des infections par vhc - Google Patents
Composés pour le traitement des infections par vhc Download PDFInfo
- Publication number
- WO2013036994A1 WO2013036994A1 PCT/AU2012/001091 AU2012001091W WO2013036994A1 WO 2013036994 A1 WO2013036994 A1 WO 2013036994A1 AU 2012001091 W AU2012001091 W AU 2012001091W WO 2013036994 A1 WO2013036994 A1 WO 2013036994A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclohexyl
- imidazo
- methyl
- optionally substituted
- amino
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 28
- 150000001875 compounds Chemical class 0.000 title claims description 154
- 241000711549 Hepacivirus C Species 0.000 claims abstract description 79
- 150000003839 salts Chemical class 0.000 claims abstract description 42
- 239000012453 solvate Substances 0.000 claims abstract description 35
- 150000004677 hydrates Chemical class 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 28
- 208000036142 Viral infection Diseases 0.000 claims abstract description 21
- 230000009385 viral infection Effects 0.000 claims abstract description 21
- 241000710781 Flaviviridae Species 0.000 claims abstract description 16
- 208000015181 infectious disease Diseases 0.000 claims abstract description 15
- 230000003612 virological effect Effects 0.000 claims abstract description 15
- 230000008569 process Effects 0.000 claims abstract description 8
- -1 cycloalkyi Chemical group 0.000 claims description 83
- 125000003118 aryl group Chemical group 0.000 claims description 50
- 125000001072 heteroaryl group Chemical group 0.000 claims description 37
- 125000000623 heterocyclic group Chemical group 0.000 claims description 33
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 31
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 31
- 125000005842 heteroatom Chemical group 0.000 claims description 31
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 claims description 31
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 30
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 27
- 229910052757 nitrogen Inorganic materials 0.000 claims description 25
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 24
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 18
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 229910052717 sulfur Inorganic materials 0.000 claims description 15
- MWBJUKMIPLQQQW-UHFFFAOYSA-N COC(=O)c1cc2[nH]c(c(C3CCCCC3)n2n1)-c1ccc(F)cc1 Chemical compound COC(=O)c1cc2[nH]c(c(C3CCCCC3)n2n1)-c1ccc(F)cc1 MWBJUKMIPLQQQW-UHFFFAOYSA-N 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 239000003443 antiviral agent Substances 0.000 claims description 13
- XDAWQJIEVMJSGY-UHFFFAOYSA-N 3-cyclohexyl-2-(4-fluorophenyl)-1-methylimidazo[1,2-b]pyrazole-6-carboxylic acid Chemical compound N12N=C(C(O)=O)C=C2N(C)C(C=2C=CC(F)=CC=2)=C1C1CCCCC1 XDAWQJIEVMJSGY-UHFFFAOYSA-N 0.000 claims description 12
- 150000001204 N-oxides Chemical class 0.000 claims description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 11
- ADBVTQQLQOMWCD-UHFFFAOYSA-N imidazo[1,5-d][1,4]benzoxazepine-10-carboxylic acid Chemical compound C1=CC2=C(C=C1C(=O)O)C3=CN=CN3C=CO2 ADBVTQQLQOMWCD-UHFFFAOYSA-N 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- AEFJZTLCCNUGGD-UHFFFAOYSA-N CCOC(=O)c1cnn2c(C3CCCCC3)c([nH]c12)-c1ccc(F)cc1 Chemical compound CCOC(=O)c1cnn2c(C3CCCCC3)c([nH]c12)-c1ccc(F)cc1 AEFJZTLCCNUGGD-UHFFFAOYSA-N 0.000 claims description 8
- 108060004795 Methyltransferase Proteins 0.000 claims description 8
- 229940123066 Polymerase inhibitor Drugs 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- RGLQJENXIYWYOM-XDHOZWIPSA-N ethyl (e)-3-[4-[[1-[[3-cyclohexyl-2-(4-fluorophenyl)-1-methylimidazo[1,2-b]pyrazole-7-carbonyl]amino]cyclobutanecarbonyl]amino]phenyl]prop-2-enoate Chemical compound C1=CC(/C=C/C(=O)OCC)=CC=C1NC(=O)C1(NC(=O)C2=C3N(C)C(C=4C=CC(F)=CC=4)=C(C4CCCCC4)N3N=C2)CCC1 RGLQJENXIYWYOM-XDHOZWIPSA-N 0.000 claims description 8
- HFHTZSVSSOMVMD-UHFFFAOYSA-N ethyl 3-cyclohexyl-2-(4-fluorophenyl)-1-methylimidazo[1,2-b]pyrazole-7-carboxylate Chemical compound C=1C=C(F)C=CC=1C=1N(C)C2=C(C(=O)OCC)C=NN2C=1C1CCCCC1 HFHTZSVSSOMVMD-UHFFFAOYSA-N 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- RDJQATOWLSKMIH-DEOSSOPVSA-N methyl (2s)-2-[[3-cyclohexyl-2-(4-fluorophenyl)-1-methylimidazo[1,2-b]pyrazole-6-carbonyl]amino]-3-(4-hydroxyphenyl)propanoate Chemical compound C([C@@H](C(=O)OC)NC(=O)C1=NN2C(C3CCCCC3)=C(N(C)C2=C1)C=1C=CC(F)=CC=1)C1=CC=C(O)C=C1 RDJQATOWLSKMIH-DEOSSOPVSA-N 0.000 claims description 8
- FYZGYNGIIGYBEA-LICLKQGHSA-N (e)-3-[4-[[1-[[3-cyclohexyl-2-(4-fluorophenyl)-1-methylimidazo[1,2-b]pyrazole-6-carbonyl]amino]cyclobutanecarbonyl]amino]phenyl]prop-2-enoic acid Chemical compound N12N=C(C(=O)NC3(CCC3)C(=O)NC=3C=CC(\C=C\C(O)=O)=CC=3)C=C2N(C)C(C=2C=CC(F)=CC=2)=C1C1CCCCC1 FYZGYNGIIGYBEA-LICLKQGHSA-N 0.000 claims description 7
- VGWUYPMQNHTBCF-UHFFFAOYSA-N 1-[(17-cyclohexyl-8-oxa-11,15,16-triazatetracyclo[9.6.0.02,7.012,16]heptadeca-1(17),2,4,6,12,14-hexaene-14-carbonyl)amino]cyclobutane-1-carboxylic acid Chemical compound C1=C2N3CCOC4=CC=CC=C4C3=C(C3CCCCC3)N2N=C1C(=O)NC1(C(=O)O)CCC1 VGWUYPMQNHTBCF-UHFFFAOYSA-N 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 239000008177 pharmaceutical agent Substances 0.000 claims description 7
- YNOWDHCGQWGMKE-LICLKQGHSA-N (e)-3-[4-[[1-[[3-cyclohexyl-2-(4-fluorophenyl)-1-methylimidazo[1,2-b]pyrazole-7-carbonyl]amino]cyclobutanecarbonyl]amino]phenyl]prop-2-enoic acid Chemical compound N12N=CC(C(=O)NC3(CCC3)C(=O)NC=3C=CC(\C=C\C(O)=O)=CC=3)=C2N(C)C(C=2C=CC(F)=CC=2)=C1C1CCCCC1 YNOWDHCGQWGMKE-LICLKQGHSA-N 0.000 claims description 6
- LXDIAPWIRJERTG-UHFFFAOYSA-N 3-cyclohexyl-1-methyl-2-phenylimidazo[1,2-b]pyrazole-7-carboxylic acid Chemical compound N12N=CC(C(O)=O)=C2N(C)C(C=2C=CC=CC=2)=C1C1CCCCC1 LXDIAPWIRJERTG-UHFFFAOYSA-N 0.000 claims description 6
- WCFCSYQLEZXEFX-UHFFFAOYSA-N 3-cyclohexyl-2-(4-fluorophenyl)-n-[2-(1h-indol-3-yl)ethyl]-1-methylimidazo[1,2-b]pyrazole-7-carboxamide Chemical compound N12N=CC(C(=O)NCCC=3C4=CC=CC=C4NC=3)=C2N(C)C(C=2C=CC(F)=CC=2)=C1C1CCCCC1 WCFCSYQLEZXEFX-UHFFFAOYSA-N 0.000 claims description 6
- SCMIYILPRBGGIF-UHFFFAOYSA-N OC(=O)c1cc2[nH]c(c(C3CCCCC3)n2n1)-c1ccc(F)cc1 Chemical compound OC(=O)c1cc2[nH]c(c(C3CCCCC3)n2n1)-c1ccc(F)cc1 SCMIYILPRBGGIF-UHFFFAOYSA-N 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- KCLMPKQICQVTSN-UHFFFAOYSA-N ethyl 3-cyclohexyl-1-methyl-2-phenylimidazo[1,2-b]pyrazole-7-carboxylate Chemical compound C=1C=CC=CC=1C=1N(C)C2=C(C(=O)OCC)C=NN2C=1C1CCCCC1 KCLMPKQICQVTSN-UHFFFAOYSA-N 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- YDKRWXAVHIBVKS-WOJGMQOQSA-N methyl (e)-3-[4-[[1-[[3-cyclohexyl-2-(4-fluorophenyl)-1-methylimidazo[1,2-b]pyrazole-6-carbonyl]amino]cyclobutanecarbonyl]amino]phenyl]prop-2-enoate Chemical compound C1=CC(/C=C/C(=O)OC)=CC=C1NC(=O)C1(NC(=O)C2=NN3C(C4CCCCC4)=C(N(C)C3=C2)C=2C=CC(F)=CC=2)CCC1 YDKRWXAVHIBVKS-WOJGMQOQSA-N 0.000 claims description 6
- 230000010076 replication Effects 0.000 claims description 6
- 125000003107 substituted aryl group Chemical group 0.000 claims description 6
- KMWKJIDSAUZFOP-OBGWFSINSA-N (e)-3-[4-[[1-[(3-cyclohexyl-1-methyl-2-phenylimidazo[1,2-b]pyrazole-7-carbonyl)amino]cyclobutanecarbonyl]amino]phenyl]prop-2-enoic acid Chemical compound N12N=CC(C(=O)NC3(CCC3)C(=O)NC=3C=CC(\C=C\C(O)=O)=CC=3)=C2N(C)C(C=2C=CC=CC=2)=C1C1CCCCC1 KMWKJIDSAUZFOP-OBGWFSINSA-N 0.000 claims description 5
- UMNPSOVMYBWPLZ-UHFFFAOYSA-N 3-cyclohexyl-2-(4-fluorophenyl)-1-methylimidazo[1,2-b]pyrazole-7-carboxylic acid Chemical compound N12N=CC(C(O)=O)=C2N(C)C(C=2C=CC(F)=CC=2)=C1C1CCCCC1 UMNPSOVMYBWPLZ-UHFFFAOYSA-N 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- NWKBQQCYUVGEDL-LVZFUZTISA-N ethyl (E)-3-[4-[[1-[(3-cyclohexyl-1-methyl-2-phenylimidazo[1,2-b]pyrazole-7-carbonyl)amino]cyclobutanecarbonyl]amino]phenyl]prop-2-enoate Chemical compound c1cc(/C=C/C(=O)OCC)ccc1NC(=O)C1(NC(=O)c2cnn3c(C4CCCCC4)c(-c4ccccc4)n(C)c32)CCC1 NWKBQQCYUVGEDL-LVZFUZTISA-N 0.000 claims description 4
- ZEUAQCNGNLGSEF-XDHOZWIPSA-N ethyl (e)-3-[4-[[1-[[3-cyclohexyl-2-(4-fluorophenyl)-1-methylimidazo[1,2-b]pyrazole-6-carbonyl]amino]cyclobutanecarbonyl]amino]phenyl]prop-2-enoate Chemical compound C1=CC(/C=C/C(=O)OCC)=CC=C1NC(=O)C1(NC(=O)C2=NN3C(C4CCCCC4)=C(N(C)C3=C2)C=2C=CC(F)=CC=2)CCC1 ZEUAQCNGNLGSEF-XDHOZWIPSA-N 0.000 claims description 4
- ZIEOIZSZSMDFJJ-UHFFFAOYSA-N methyl 17-cyclohexyl-8-oxa-11,15,16-triazatetracyclo[9.6.0.02,7.012,16]heptadeca-1(17),2,4,6,12,14-hexaene-14-carboxylate Chemical compound N12N=C(C(=O)OC)C=C2N2CCOC3=CC=CC=C3C2=C1C1CCCCC1 ZIEOIZSZSMDFJJ-UHFFFAOYSA-N 0.000 claims description 4
- WCHMINXFGKHDGS-UHFFFAOYSA-N methyl 3-cyclohexyl-2-(4-fluorophenyl)-1-methylimidazo[1,2-b]pyrazole-6-carboxylate Chemical compound N12N=C(C(=O)OC)C=C2N(C)C(C=2C=CC(F)=CC=2)=C1C1CCCCC1 WCHMINXFGKHDGS-UHFFFAOYSA-N 0.000 claims description 4
- SBVZMYPDBCXNAL-UHFFFAOYSA-N 17-cyclohexyl-5-[[2-morpholin-4-yl-5-(2-oxopyrrolidin-1-yl)phenyl]methoxy]-8-oxa-11,13,16-triazatetracyclo[9.6.0.02,7.012,16]heptadeca-1(17),2(7),3,5,12,14-hexaene-14-carboxylic acid Chemical compound C=12C3=CC=C(OCC=4C(=CC=C(C=4)N4C(CCC4)=O)N4CCOCC4)C=C3OCCN2C2=NC(C(=O)O)=CN2C=1C1CCCCC1 SBVZMYPDBCXNAL-UHFFFAOYSA-N 0.000 claims description 3
- ZQXTWZVMTHPXAX-UHFFFAOYSA-N 3-cyclohexyl-2-(4-fluorophenyl)-1-methylimidazo[1,2-b]pyrazole Chemical compound N12N=CC=C2N(C)C(C=2C=CC(F)=CC=2)=C1C1CCCCC1 ZQXTWZVMTHPXAX-UHFFFAOYSA-N 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- XKJSBFZMKMSFGS-UHFFFAOYSA-N C=1C=C2C3=C(C4CCCCC4)N4N=C(C(=O)O)C=C4N3CCOC2=CC=1OCC1=CC(N2C(CCC2)=O)=CC=C1N1CCOCC1 Chemical compound C=1C=C2C3=C(C4CCCCC4)N4N=C(C(=O)O)C=C4N3CCOC2=CC=1OCC1=CC(N2C(CCC2)=O)=CC=C1N1CCOCC1 XKJSBFZMKMSFGS-UHFFFAOYSA-N 0.000 claims description 2
- XWOZMOOMAWVVBH-UHFFFAOYSA-N N12N=C(C(=O)OC)C=C2N2CCOC3=CC(O)=CC=C3C2=C1C1CCCCC1 Chemical compound N12N=C(C(=O)OC)C=C2N2CCOC3=CC(O)=CC=C3C2=C1C1CCCCC1 XWOZMOOMAWVVBH-UHFFFAOYSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 230000009435 amidation Effects 0.000 claims description 2
- 238000007112 amidation reaction Methods 0.000 claims description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- QJRDWZHZXJHLBB-UHFFFAOYSA-N 17-cyclohexyl-5-phenylmethoxy-8-oxa-11,15,16-triazatetracyclo[9.6.0.02,7.012,16]heptadeca-1(17),2(7),3,5,12,14-hexaene-14-carboxylic acid Chemical compound C=1C=C2C3=C(C4CCCCC4)N4N=C(C(=O)O)C=C4N3CCOC2=CC=1OCC1=CC=CC=C1 QJRDWZHZXJHLBB-UHFFFAOYSA-N 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- QWMIYZSGAOTKPN-UHFFFAOYSA-N N12N=C(C(=O)O)C=C2N2CCOC3=CC=CC=C3C2=C1C1CCCCC1 Chemical compound N12N=C(C(=O)O)C=C2N2CCOC3=CC=CC=C3C2=C1C1CCCCC1 QWMIYZSGAOTKPN-UHFFFAOYSA-N 0.000 claims 1
- YYKRKQOLFNSWIA-UHFFFAOYSA-N methyl 17-cyclohexyl-5-phenylmethoxy-8-oxa-11,15,16-triazatetracyclo[9.6.0.02,7.012,16]heptadeca-1(17),2(7),3,5,12,14-hexaene-14-carboxylate Chemical compound C=1C=C2C3=C(C4CCCCC4)N4N=C(C(=O)OC)C=C4N3CCOC2=CC=1OCC1=CC=CC=C1 YYKRKQOLFNSWIA-UHFFFAOYSA-N 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 24
- 238000002360 preparation method Methods 0.000 abstract description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 134
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 75
- 239000000243 solution Substances 0.000 description 70
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 69
- 235000019439 ethyl acetate Nutrition 0.000 description 66
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 55
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 54
- 239000011541 reaction mixture Substances 0.000 description 48
- 239000007787 solid Substances 0.000 description 48
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 46
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 40
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 39
- 239000012267 brine Substances 0.000 description 37
- 239000012071 phase Substances 0.000 description 37
- 238000000746 purification Methods 0.000 description 37
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 37
- 239000000203 mixture Substances 0.000 description 33
- 229910002092 carbon dioxide Inorganic materials 0.000 description 30
- 239000003921 oil Substances 0.000 description 30
- 235000019198 oils Nutrition 0.000 description 30
- 239000010410 layer Substances 0.000 description 28
- 230000002441 reversible effect Effects 0.000 description 28
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 26
- 238000003786 synthesis reaction Methods 0.000 description 26
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 25
- 238000010828 elution Methods 0.000 description 25
- 238000005160 1H NMR spectroscopy Methods 0.000 description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 24
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 23
- 239000000377 silicon dioxide Substances 0.000 description 23
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 22
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 19
- 239000012044 organic layer Substances 0.000 description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- 238000005481 NMR spectroscopy Methods 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 239000007864 aqueous solution Substances 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 150000001408 amides Chemical class 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 239000012298 atmosphere Substances 0.000 description 14
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 13
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 13
- WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 13
- 239000002775 capsule Substances 0.000 description 13
- 235000019253 formic acid Nutrition 0.000 description 13
- 239000001257 hydrogen Substances 0.000 description 13
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- 125000003710 aryl alkyl group Chemical group 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 229910052786 argon Inorganic materials 0.000 description 11
- 125000004122 cyclic group Chemical group 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 239000007821 HATU Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 238000004108 freeze drying Methods 0.000 description 10
- 229960000329 ribavirin Drugs 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 238000010626 work up procedure Methods 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 description 9
- IBYHHJPAARCAIE-UHFFFAOYSA-N 1-bromo-2-chloroethane Chemical compound ClCCBr IBYHHJPAARCAIE-UHFFFAOYSA-N 0.000 description 8
- 108010050904 Interferons Proteins 0.000 description 8
- 102000014150 Interferons Human genes 0.000 description 8
- 125000002619 bicyclic group Chemical group 0.000 description 8
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 description 8
- 239000013058 crude material Substances 0.000 description 8
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 8
- 229940079322 interferon Drugs 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 125000003368 amide group Chemical group 0.000 description 7
- 230000000840 anti-viral effect Effects 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 125000002950 monocyclic group Chemical group 0.000 description 7
- 239000002777 nucleoside Substances 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 150000003456 sulfonamides Chemical class 0.000 description 7
- 108010017101 telaprevir Proteins 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- OKDQCKXTMHPAQF-UHFFFAOYSA-N 2-bromo-1-[2-(2-chloroethoxy)-4-phenylmethoxyphenyl]-2-cyclohexylethanone Chemical compound C=1C=C(C(=O)C(Br)C2CCCCC2)C(OCCCl)=CC=1OCC1=CC=CC=C1 OKDQCKXTMHPAQF-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 229960000517 boceprevir Drugs 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- 125000002837 carbocyclic group Chemical group 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 150000001733 carboxylic acid esters Chemical class 0.000 description 6
- FKRSSPOQAMALKA-CUPIEXAXSA-N daclatasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)=CN1 FKRSSPOQAMALKA-CUPIEXAXSA-N 0.000 description 6
- 229960005449 daclatasvir Drugs 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 150000003833 nucleoside derivatives Chemical class 0.000 description 6
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 229940124530 sulfonamide Drugs 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 5
- 101710144111 Non-structural protein 3 Proteins 0.000 description 5
- 101800001014 Non-structural protein 5A Proteins 0.000 description 5
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 5
- 108010052090 Renilla Luciferases Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 125000004430 oxygen atom Chemical group O* 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 5
- 229960002935 telaprevir Drugs 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- IQBTULQAZUUVMY-UHFFFAOYSA-N 17-cyclohexyl-5-phenylmethoxy-8-oxa-11,13,16-triazatetracyclo[9.6.0.02,7.012,16]heptadeca-1(17),2(7),3,5,12,14-hexaene-14-carboxylic acid Chemical compound C=12C3=CC=C(OCC=4C=CC=CC=4)C=C3OCCN2C2=NC(C(=O)O)=CN2C=1C1CCCCC1 IQBTULQAZUUVMY-UHFFFAOYSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 4
- 241000711557 Hepacivirus Species 0.000 description 4
- 208000005176 Hepatitis C Diseases 0.000 description 4
- 102000016600 Inosine-5'-monophosphate dehydrogenases Human genes 0.000 description 4
- 108050006182 Inosine-5'-monophosphate dehydrogenases Proteins 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 4
- 230000007882 cirrhosis Effects 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- HPAPGONEMPZXMM-CMWVUSIZSA-N vaniprevir Chemical compound O=C([C@H]1C[C@@H]2OC(=O)N3CC=4C=CC=C(C=4C3)CCCCC(C)(C)COC(=O)N[C@@H](C(N1C2)=O)C(C)(C)C)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C HPAPGONEMPZXMM-CMWVUSIZSA-N 0.000 description 4
- 229950000843 vaniprevir Drugs 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- MYGPNCKSHRFZOR-UHFFFAOYSA-N 1-[2-(2-chloroethoxy)-4-phenylmethoxyphenyl]-2-cyclohexylethanone Chemical compound C=1C=C(C(=O)CC2CCCCC2)C(OCCCl)=CC=1OCC1=CC=CC=C1 MYGPNCKSHRFZOR-UHFFFAOYSA-N 0.000 description 3
- FAWNITZNDQDZNE-UHFFFAOYSA-N 2-bromo-2-cyclohexyl-1-(4-fluorophenyl)ethanone Chemical compound C1=CC(F)=CC=C1C(=O)C(Br)C1CCCCC1 FAWNITZNDQDZNE-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 3
- SHXIFKXWIWGOOI-UHFFFAOYSA-N C=12C3=CC=C(OCC=4C=CC=CC=4)C=C3OCCN2C2=NC(C(=O)OCC)=CN2C=1C1CCCCC1 Chemical compound C=12C3=CC=C(OCC=4C=CC=CC=4)C=C3OCCN2C2=NC(C(=O)OCC)=CN2C=1C1CCCCC1 SHXIFKXWIWGOOI-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 241000710831 Flavivirus Species 0.000 description 3
- 229940124683 HCV polymerase inhibitor Drugs 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 108091027544 Subgenomic mRNA Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 239000011149 active material Substances 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- PYRZPBDTPRQYKG-UHFFFAOYSA-N cyclopentene-1-carboxylic acid Chemical compound OC(=O)C1=CCCC1 PYRZPBDTPRQYKG-UHFFFAOYSA-N 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- ZVTDLPBHTSMEJZ-JSZLBQEHSA-N danoprevir Chemical compound O=C([C@@]12C[C@H]1\C=C/CCCCC[C@@H](C(N1C[C@@H](C[C@H]1C(=O)N2)OC(=O)N1CC2=C(F)C=CC=C2C1)=O)NC(=O)OC(C)(C)C)NS(=O)(=O)C1CC1 ZVTDLPBHTSMEJZ-JSZLBQEHSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000012909 foetal bovine serum Substances 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 125000006574 non-aromatic ring group Chemical group 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 125000005458 thianyl group Chemical group 0.000 description 3
- 229960004799 tryptophan Drugs 0.000 description 3
- 229960004441 tyrosine Drugs 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 2
- CATAFHVAAHWYDS-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-(1-hydroxycyclohexyl)ethanone Chemical compound C=1C=C(F)C=CC=1C(=O)CC1(O)CCCCC1 CATAFHVAAHWYDS-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- KNGQZAMUCKGREX-UHFFFAOYSA-N 1-[2-(2-chloroethoxy)phenyl]-2-(1-hydroxycyclohexyl)ethanone Chemical compound C=1C=CC=C(OCCCl)C=1C(=O)CC1(O)CCCCC1 KNGQZAMUCKGREX-UHFFFAOYSA-N 0.000 description 2
- GHCVYGOAUMGRTM-UHFFFAOYSA-N 1-[2-(2-chloroethoxy)phenyl]-2-cyclohexylethanone Chemical compound ClCCOC1=CC=CC=C1C(=O)CC1CCCCC1 GHCVYGOAUMGRTM-UHFFFAOYSA-N 0.000 description 2
- FZXVDBULFTUKTM-UHFFFAOYSA-N 1-[2-(2-chloroethoxy)phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1OCCCl FZXVDBULFTUKTM-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- JECYUBVRTQDVAT-UHFFFAOYSA-N 2-acetylphenol Chemical compound CC(=O)C1=CC=CC=C1O JECYUBVRTQDVAT-UHFFFAOYSA-N 0.000 description 2
- RVZTVZJTWFEGTA-UHFFFAOYSA-N 2-bromo-1-[2-(2-chloroethoxy)phenyl]-2-cyclohexylethanone Chemical compound ClCCOC1=CC=CC=C1C(=O)C(Br)C1CCCCC1 RVZTVZJTWFEGTA-UHFFFAOYSA-N 0.000 description 2
- QAAXCPPQXMLTBL-UHFFFAOYSA-N 2-cyclohexyl-1-(2,4-dihydroxyphenyl)ethanone Chemical compound OC1=CC(O)=CC=C1C(=O)CC1CCCCC1 QAAXCPPQXMLTBL-UHFFFAOYSA-N 0.000 description 2
- WWGPFVUANRESTL-UHFFFAOYSA-N 2-cyclohexyl-1-(2-hydroxy-4-phenylmethoxyphenyl)ethanone Chemical compound C=1C=C(C(=O)CC2CCCCC2)C(O)=CC=1OCC1=CC=CC=C1 WWGPFVUANRESTL-UHFFFAOYSA-N 0.000 description 2
- SBKROAPUFJFGHY-UHFFFAOYSA-N 2-cyclohexyl-1-(4-fluorophenyl)ethanone Chemical compound C1=CC(F)=CC=C1C(=O)CC1CCCCC1 SBKROAPUFJFGHY-UHFFFAOYSA-N 0.000 description 2
- ZWVXMGIAPJZXCO-UHFFFAOYSA-N 2-cyclohexyl-1-phenylethanone Chemical compound C=1C=CC=CC=1C(=O)CC1CCCCC1 ZWVXMGIAPJZXCO-UHFFFAOYSA-N 0.000 description 2
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 2
- JZIBVTUXIVIFGC-UHFFFAOYSA-N 2H-pyrrole Chemical compound C1C=CC=N1 JZIBVTUXIVIFGC-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 2
- XBEQSQDCBSKCHJ-UHFFFAOYSA-N 5-[[6-[2,4-bis(trifluoromethyl)phenyl]pyridazin-3-yl]methyl]-2-(2-fluorophenyl)imidazo[4,5-c]pyridine Chemical compound FC1=CC=CC=C1C1=NC2=CN(CC=3N=NC(=CC=3)C=3C(=CC(=CC=3)C(F)(F)F)C(F)(F)F)C=CC2=N1 XBEQSQDCBSKCHJ-UHFFFAOYSA-N 0.000 description 2
- 125000001960 7 membered carbocyclic group Chemical group 0.000 description 2
- RFGUWOCFYCYEDM-ZOMNBDOOSA-N 8v42y78hru Chemical compound OP([C@@]12C[C@H]1CCCCCCC[C@@H](C(=O)N1[C@H](C(N2)=O)C[C@H](C1)OC=1C2=CC=C(C(=C2N=C(C=1)C=1N=C(NC(C)C)SC=1)Cl)OC)NC(=O)OC1CCCC1)(=O)CC1=C(F)C=CC=C1F RFGUWOCFYCYEDM-ZOMNBDOOSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 102100040018 Interferon alpha-2 Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010079944 Interferon-alpha2b Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- YEPBUHWNLNKZBW-UEMKMYPFSA-N O=C([C@]12NC(=O)[C@H]3N(C(N(C)CCCC\C=C/[C@@H]1C2)=O)CC[C@@H](C3)OC=1C2=CC=C(C(=C2N=C(C=1)C=1SC=C(N=1)C(F)(F)F)C)OC)NS(=O)(=O)C1(C)CC1 Chemical compound O=C([C@]12NC(=O)[C@H]3N(C(N(C)CCCC\C=C/[C@@H]1C2)=O)CC[C@@H](C3)OC=1C2=CC=C(C(=C2N=C(C=1)C=1SC=C(N=1)C(F)(F)F)C)OC)NS(=O)(=O)C1(C)CC1 YEPBUHWNLNKZBW-UEMKMYPFSA-N 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 241000710778 Pestivirus Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 230000006819 RNA synthesis Effects 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- MHFMTUBUVQZIRE-WINRQGAFSA-N Sovaprevir Chemical compound C([C@H](C(=O)N1[C@@H](C[C@H](C1)OC=1C2=CC=C(C=C2N=C(C=1)C=1C=CC=CC=1)OC)C(=O)N[C@]1([C@@H](C1)C=C)C(=O)NS(=O)(=O)C1CC1)C(C)(C)C)C(=O)N1CCCCC1 MHFMTUBUVQZIRE-WINRQGAFSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- MLESJYFEMSJZLZ-MAAOGQSESA-N [(2r,3r,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-4-methyl-3-(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate Chemical compound C[C@@]1(F)[C@H](OC(=O)C(C)C)[C@@H](COC(=O)C(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 MLESJYFEMSJZLZ-MAAOGQSESA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 2
- 229960002118 asunaprevir Drugs 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- 125000003828 azulenyl group Chemical group 0.000 description 2
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940045348 brown mixture Drugs 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 229950002891 danoprevir Drugs 0.000 description 2
- UDMJANYPQWEDFT-ZAWFUYGJSA-N deldeprevir Chemical compound C([C@@H]1C(=O)N2[C@H](C(N[C@@]3(C[C@H]3\C=C/CCCCC1)C(=O)NS(=O)(=O)C1CC1)=O)C[C@H](C2)OC=1C2=CC=C(C(=C2N=C(C=1)C=1SC=C(N=1)C(C)C)C)OC)C(=O)N1CCCC(F)(F)C1 UDMJANYPQWEDFT-ZAWFUYGJSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- MFLKZYDHTXFUJJ-MLBSPLJJSA-N ethyl (e)-3-[4-[(1-aminocyclobutanecarbonyl)amino]phenyl]prop-2-enoate;hydrochloride Chemical compound Cl.C1=CC(/C=C/C(=O)OCC)=CC=C1NC(=O)C1(N)CCC1 MFLKZYDHTXFUJJ-MLBSPLJJSA-N 0.000 description 2
- KSUIMSWAPUAHBC-UHFFFAOYSA-N ethyl 17-cyclohexyl-5-[[2-morpholin-4-yl-5-(2-oxopyrrolidin-1-yl)phenyl]methoxy]-8-oxa-11,13,16-triazatetracyclo[9.6.0.02,7.012,16]heptadeca-1(17),2(7),3,5,12,14-hexaene-14-carboxylate Chemical compound C=12C3=CC=C(OCC=4C(=CC=C(C=4)N4C(CCC4)=O)N4CCOCC4)C=C3OCCN2C2=NC(C(=O)OCC)=CN2C=1C1CCCCC1 KSUIMSWAPUAHBC-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- SLVAPEZTBDBAPI-GDLZYMKVSA-N filibuvir Chemical compound CCC1=NC(CC)=CC(CC[C@]2(OC(=O)C(CC3=NN4C(C)=CC(C)=NC4=N3)=C(O)C2)C2CCCC2)=C1 SLVAPEZTBDBAPI-GDLZYMKVSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- OBMNJSNZOWALQB-NCQNOWPTSA-N grazoprevir Chemical compound O=C([C@@H]1C[C@@H]2CN1C(=O)[C@@H](NC(=O)O[C@@H]1C[C@H]1CCCCCC1=NC3=CC=C(C=C3N=C1O2)OC)C(C)(C)C)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C OBMNJSNZOWALQB-NCQNOWPTSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940084039 incivek Drugs 0.000 description 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- YMCAVGXTSCNFDE-BBACVFHCSA-N methyl n-[(2s)-1-[(2s)-2-[5-[4-[4-[2-[(8s)-7-[(2s)-2-(methoxycarbonylamino)-3-methylbutanoyl]-1,4-dioxa-7-azaspiro[4.4]nonan-8-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CC3(C2)OCCO3)C(=O)[C@@H](NC(=O)OC)C(C)C)N1 YMCAVGXTSCNFDE-BBACVFHCSA-N 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- RICZEKWVNZFTNZ-LFGITCQGSA-N narlaprevir Chemical compound N([C@H](C(=O)N1C[C@H]2[C@H](C2(C)C)[C@H]1C(=O)N[C@@H](CCCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1 RICZEKWVNZFTNZ-LFGITCQGSA-N 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
- 229960000518 ombitasvir Drugs 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- UAUIUKWPKRJZJV-MDJGTQRPSA-N paritaprevir Chemical compound C1=NC(C)=CN=C1C(=O)N[C@@H]1C(=O)N2C[C@H](OC=3C4=CC=CC=C4C4=CC=CC=C4N=3)C[C@H]2C(=O)N[C@]2(C(=O)NS(=O)(=O)C3CC3)C[C@@H]2\C=C/CCCCC1 UAUIUKWPKRJZJV-MDJGTQRPSA-N 0.000 description 2
- 229960002754 paritaprevir Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000005897 peptide coupling reaction Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- IMACFCSSMIZSPP-UHFFFAOYSA-N phenacyl chloride Chemical compound ClCC(=O)C1=CC=CC=C1 IMACFCSSMIZSPP-UHFFFAOYSA-N 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- JTZZSQYMACOLNN-VDWJNHBNSA-N simeprevir Chemical compound O=C([C@@]12C[C@H]1\C=C/CCCCN(C)C(=O)[C@H]1[C@H](C(N2)=O)C[C@H](C1)OC=1C2=CC=C(C(=C2N=C(C=1)C=1SC=C(N=1)C(C)C)C)OC)NS(=O)(=O)C1CC1 JTZZSQYMACOLNN-VDWJNHBNSA-N 0.000 description 2
- 229960002091 simeprevir Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000003019 stabilising effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 125000000464 thioxo group Chemical group S=* 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- 229940086210 victrelis Drugs 0.000 description 2
- 230000007502 viral entry Effects 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- RNEACARJKXYVND-KQGZCTBQSA-N (2r)-2-[[(5z)-5-[(5-ethylfuran-2-yl)methylidene]-4-oxo-1,3-thiazol-2-yl]amino]-2-(4-fluorophenyl)acetic acid Chemical compound O1C(CC)=CC=C1\C=C/1C(=O)N=C(N[C@@H](C(O)=O)C=2C=CC(F)=CC=2)S\1 RNEACARJKXYVND-KQGZCTBQSA-N 0.000 description 1
- JQLOVYLALGSISI-HXUWFJFHSA-N (2r)-4-(5-cyclopropyl-[1,3]thiazolo[4,5-d]pyrimidin-2-yl)-n-[[3-fluoro-4-(trifluoromethoxy)phenyl]methyl]-1-[4-(trifluoromethyl)phenyl]sulfonylpiperazine-2-carboxamide Chemical compound C1=C(OC(F)(F)F)C(F)=CC(CNC(=O)[C@@H]2N(CCN(C2)C=2SC3=CN=C(N=C3N=2)C2CC2)S(=O)(=O)C=2C=CC(=CC=2)C(F)(F)F)=C1 JQLOVYLALGSISI-HXUWFJFHSA-N 0.000 description 1
- RLGAXHNBEXKRIZ-NAFKDRLFSA-N (3r,4r,5r)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)OC1C1=CC=C2N1N=CN=C2N RLGAXHNBEXKRIZ-NAFKDRLFSA-N 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- FQERLIOIVXPZKH-UHFFFAOYSA-N 1,2,4-trioxane Chemical compound C1COOCO1 FQERLIOIVXPZKH-UHFFFAOYSA-N 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- HKDFRDIIELOLTJ-UHFFFAOYSA-N 1,4-dithianyl Chemical group [CH]1CSCCS1 HKDFRDIIELOLTJ-UHFFFAOYSA-N 0.000 description 1
- 125000000183 1,4-thiazinyl group Chemical group S1C(C=NC=C1)* 0.000 description 1
- VMLKTERJLVWEJJ-UHFFFAOYSA-N 1,5-naphthyridine Chemical compound C1=CC=NC2=CC=CN=C21 VMLKTERJLVWEJJ-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- ZDPAWHACYDRYIW-UHFFFAOYSA-N 1-(4-fluorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(F)C=C1 ZDPAWHACYDRYIW-UHFFFAOYSA-N 0.000 description 1
- URCUVMZEJNVKEW-UHFFFAOYSA-N 1-[3-(chloromethyl)-4-morpholin-4-ylphenyl]pyrrolidin-2-one Chemical compound ClCC1=CC(N2C(CCC2)=O)=CC=C1N1CCOCC1 URCUVMZEJNVKEW-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- MFJCPDOGFAYSTF-UHFFFAOYSA-N 1H-isochromene Chemical compound C1=CC=C2COC=CC2=C1 MFJCPDOGFAYSTF-UHFFFAOYSA-N 0.000 description 1
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 description 1
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical group C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 1
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical group C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 description 1
- YFXGICNMLCGLHJ-RSKRLRQZSA-N 2,2-dimethylpropyl (2s)-2-[[[(2r,3r,4r,5r)-5-(2-amino-6-methoxypurin-9-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-naphthalen-1-yloxyphosphoryl]amino]propanoate Chemical compound C1=CC=C2C(OP(=O)(N[C@@H](C)C(=O)OCC(C)(C)C)OC[C@H]3O[C@H]([C@]([C@@H]3O)(C)O)N3C=4N=C(N)N=C(C=4N=C3)OC)=CC=CC2=C1 YFXGICNMLCGLHJ-RSKRLRQZSA-N 0.000 description 1
- FJRPOHLDJUJARI-UHFFFAOYSA-N 2,3-dihydro-1,2-oxazole Chemical compound C1NOC=C1 FJRPOHLDJUJARI-UHFFFAOYSA-N 0.000 description 1
- ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical compound C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 description 1
- YJUFGFXVASPYFQ-UHFFFAOYSA-N 2,3-dihydro-1-benzothiophene Chemical compound C1=CC=C2SCCC2=C1 YJUFGFXVASPYFQ-UHFFFAOYSA-N 0.000 description 1
- FLNPFFMWAPTGOT-UHFFFAOYSA-N 2,3-dihydro-1h-pyrazole Chemical compound C1NNC=C1.C1NNC=C1 FLNPFFMWAPTGOT-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- NODQISXANKQTQO-UHFFFAOYSA-N 2-bromo-2-cyclohexyl-1-phenylethanone Chemical compound C=1C=CC=CC=1C(=O)C(Br)C1CCCCC1 NODQISXANKQTQO-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- VABYVFZVTIDNOA-UHFFFAOYSA-N 2-cyclohexylacetyl chloride Chemical compound ClC(=O)CC1CCCCC1 VABYVFZVTIDNOA-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- CMLFRMDBDNHMRA-UHFFFAOYSA-N 2h-1,2-benzoxazine Chemical compound C1=CC=C2C=CNOC2=C1 CMLFRMDBDNHMRA-UHFFFAOYSA-N 0.000 description 1
- UMZCLZPXPCNKML-UHFFFAOYSA-N 2h-imidazo[4,5-d][1,3]thiazole Chemical compound C1=NC2=NCSC2=N1 UMZCLZPXPCNKML-UHFFFAOYSA-N 0.000 description 1
- QMEQBOSUJUOXMX-UHFFFAOYSA-N 2h-oxadiazine Chemical compound N1OC=CC=N1 QMEQBOSUJUOXMX-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- BOLMDIXLULGTBD-UHFFFAOYSA-N 3,4-dihydro-2h-oxazine Chemical compound C1CC=CON1 BOLMDIXLULGTBD-UHFFFAOYSA-N 0.000 description 1
- WPWNEKFMGCWNPR-UHFFFAOYSA-N 3,4-dihydro-2h-thiochromene Chemical compound C1=CC=C2CCCSC2=C1 WPWNEKFMGCWNPR-UHFFFAOYSA-N 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- VXIKDBJPBRMXBP-UHFFFAOYSA-N 3H-pyrrole Chemical compound C1C=CN=C1 VXIKDBJPBRMXBP-UHFFFAOYSA-N 0.000 description 1
- XDADYJOYIMVXTH-UHFFFAOYSA-N 3h-imidazo[1,2-a]imidazole Chemical compound C1=CN2CC=NC2=N1 XDADYJOYIMVXTH-UHFFFAOYSA-N 0.000 description 1
- RELAJOWOFXGXHI-UHFFFAOYSA-N 3h-oxathiole Chemical compound C1SOC=C1 RELAJOWOFXGXHI-UHFFFAOYSA-N 0.000 description 1
- YCVAGNVTZICLNM-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1-benzofuran Chemical compound C1CCCC2=C1C=CO2 YCVAGNVTZICLNM-UHFFFAOYSA-N 0.000 description 1
- CZMMHNSAYMBDRN-UHFFFAOYSA-N 4-[2-(chloromethyl)-4-pyrrolidin-1-ylphenyl]morpholine Chemical compound ClCC=1C=C(C=CC=1N1CCOCC1)N1CCCC1 CZMMHNSAYMBDRN-UHFFFAOYSA-N 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- MUICUPWICXUNRS-UVXQUXCMSA-N 5-(3,3-dimethylbut-1-ynyl)-3-[[4-hydroxy-4-[[(3s)-oxolan-3-yl]oxymethyl]cyclohexyl]-[(1r)-4-methylcyclohex-3-ene-1-carbonyl]amino]thiophene-2-carboxylic acid Chemical compound C1CC(C)=CC[C@@H]1C(=O)N(C1=C(SC(=C1)C#CC(C)(C)C)C(O)=O)C1CCC(O)(CO[C@@H]2COCC2)CC1 MUICUPWICXUNRS-UVXQUXCMSA-N 0.000 description 1
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
- PVRFQJIRERYGTQ-DSQUMVBZSA-N 9-[(2s,4ar,6r,7r,7ar)-7-fluoro-7-methyl-2-oxo-2-propan-2-yloxy-4,4a,6,7a-tetrahydrofuro[3,2-d][1,3,2]dioxaphosphinin-6-yl]-6-ethoxypurin-2-amine Chemical compound C([C@H]1O2)O[P@@](=O)(OC(C)C)O[C@H]1[C@](F)(C)[C@@H]2N1C(N=C(N)N=C2OCC)=C2N=C1 PVRFQJIRERYGTQ-DSQUMVBZSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035049 Blood-Borne Infections Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101710118188 DNA-binding protein HU-alpha Proteins 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 101710144128 Non-structural protein 2 Proteins 0.000 description 1
- 101800001020 Non-structural protein 4A Proteins 0.000 description 1
- 101800001019 Non-structural protein 4B Proteins 0.000 description 1
- 101710199667 Nuclear export protein Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- GNSXDDLDAGAXTL-UHFFFAOYSA-N S1OCCCC1.O1SCCCC1 Chemical compound S1OCCCC1.O1SCCCC1 GNSXDDLDAGAXTL-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 206010051511 Viral diarrhoea Diseases 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- IUAYJYAXWLQCIR-UHFFFAOYSA-N [Ar].CC[SiH](CC)CC Chemical compound [Ar].CC[SiH](CC)CC IUAYJYAXWLQCIR-UHFFFAOYSA-N 0.000 description 1
- WMJMABVHDMRMJA-UHFFFAOYSA-M [Cl-].[Mg+]C1CCCCC1 Chemical compound [Cl-].[Mg+]C1CCCCC1 WMJMABVHDMRMJA-UHFFFAOYSA-M 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000004171 alkoxy aryl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 1
- NXJYUAYKUDPKBN-UHFFFAOYSA-N argon;2-bromo-2-cyclohexyl-1-phenylethanone Chemical compound [Ar].C=1C=CC=CC=1C(=O)C(Br)C1CCCCC1 NXJYUAYKUDPKBN-UHFFFAOYSA-N 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000004421 aryl sulphonamide group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- AAMATCKFMHVIDO-UHFFFAOYSA-N azane;1h-pyrrole Chemical compound N.C=1C=CNC=1 AAMATCKFMHVIDO-UHFFFAOYSA-N 0.000 description 1
- CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical group N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical compound C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 description 1
- WPMJNLCLKAKMLA-VVPTUSLJSA-N chembl3039503 Chemical compound C1C[C@@H](C)CC[C@@H]1C(=O)N(C1=C(SC(=C1)C#CC(C)(C)C)C(O)=O)[C@@H]1CC[C@@H](O)CC1 WPMJNLCLKAKMLA-VVPTUSLJSA-N 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000010549 co-Evaporation Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 229940055354 copegus Drugs 0.000 description 1
- ZKXWKVVCCTZOLD-UHFFFAOYSA-N copper;4-hydroxypent-3-en-2-one Chemical compound [Cu].CC(O)=CC(C)=O.CC(O)=CC(C)=O ZKXWKVVCCTZOLD-UHFFFAOYSA-N 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NBRBXGKOEOGLOI-UHFFFAOYSA-N dasabuvir Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C=C1N1C=CC(=O)NC1=O NBRBXGKOEOGLOI-UHFFFAOYSA-N 0.000 description 1
- 229960001418 dasabuvir Drugs 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- BMAIGAHXAJEULY-UKTHLTGXSA-N deleobuvir Chemical compound C12=CC=C(C(=O)NC3(CCC3)C=3N(C4=CC(\C=C\C(O)=O)=CC=C4N=3)C)C=C2N(C)C(C=2N=CC(Br)=CN=2)=C1C1CCCC1 BMAIGAHXAJEULY-UKTHLTGXSA-N 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 1
- HGGNZMUHOHGHBJ-UHFFFAOYSA-N dioxepane Chemical compound C1CCOOCC1 HGGNZMUHOHGHBJ-UHFFFAOYSA-N 0.000 description 1
- 125000000597 dioxinyl group Chemical group 0.000 description 1
- QTGBDKMESBAKDY-UHFFFAOYSA-L dipotassium argon carbonate Chemical compound [Ar].C([O-])([O-])=O.[K+].[K+] QTGBDKMESBAKDY-UHFFFAOYSA-L 0.000 description 1
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 1
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 235000019564 dysgeusia Nutrition 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- NRPMBSHHBFFYBF-VMPITWQZSA-N ethyl (e)-3-(4-aminophenyl)prop-2-enoate Chemical compound CCOC(=O)\C=C\C1=CC=C(N)C=C1 NRPMBSHHBFFYBF-VMPITWQZSA-N 0.000 description 1
- WOZYNAYJPQTSRY-RMKNXTFCSA-N ethyl (e)-3-[4-[(1-aminocyclobutanecarbonyl)amino]phenyl]prop-2-enoate Chemical compound C1=CC(/C=C/C(=O)OCC)=CC=C1NC(=O)C1(N)CCC1 WOZYNAYJPQTSRY-RMKNXTFCSA-N 0.000 description 1
- YGAYWFFKRVMVBL-UHFFFAOYSA-N ethyl 1-aminocyclobutane-1-carboxylate;hydrochloride Chemical compound Cl.CCOC(=O)C1(N)CCC1 YGAYWFFKRVMVBL-UHFFFAOYSA-N 0.000 description 1
- RHKBFKQYNKOAEA-UHFFFAOYSA-N ethyl 17-cyclohexyl-5-hydroxy-8-oxa-11,13,16-triazatetracyclo[9.6.0.02,7.012,16]heptadeca-1(17),2(7),3,5,12,14-hexaene-14-carboxylate Chemical compound C=12C3=CC=C(O)C=C3OCCN2C2=NC(C(=O)OCC)=CN2C=1C1CCCCC1 RHKBFKQYNKOAEA-UHFFFAOYSA-N 0.000 description 1
- YPXGHKWOJXQLQU-UHFFFAOYSA-N ethyl 5-amino-1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNC=1N YPXGHKWOJXQLQU-UHFFFAOYSA-N 0.000 description 1
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- LLGDPTDZOVKFDU-XUHJSTDZSA-N faldaprevir Chemical compound N([C@H](C(=O)N1[C@@H](C[C@H](C1)OC=1C2=CC=C(C(=C2N=C(C=1)C=1N=C(NC(=O)C(C)C)SC=1)Br)OC)C(=O)N[C@]1([C@@H](C1)C=C)C(O)=O)C(C)(C)C)C(=O)OC1CCCC1 LLGDPTDZOVKFDU-XUHJSTDZSA-N 0.000 description 1
- 229950011045 filibuvir Drugs 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFBBWLWUIISIPW-UHFFFAOYSA-N imidazo[2,1-b][1,3]thiazole Chemical compound C1=CSC2=NC=CN21 UFBBWLWUIISIPW-UHFFFAOYSA-N 0.000 description 1
- CQQJSOXDEFZGFG-UHFFFAOYSA-N imidazo[4,5-d]imidazole Chemical compound C1=NC2=NC=NC2=N1 CQQJSOXDEFZGFG-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 229940090438 infergen Drugs 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 108010010648 interferon alfacon-1 Proteins 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- HEBMCVBCEDMUOF-UHFFFAOYSA-N isochromane Chemical compound C1=CC=C2COCCC2=C1 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 229950010383 mericitabine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- XNFNGGQRDXFYMM-PPHPATTJSA-N methyl (2s)-2-amino-3-(1h-indol-3-yl)propanoate;hydrochloride Chemical compound Cl.C1=CC=C2C(C[C@H](N)C(=O)OC)=CNC2=C1 XNFNGGQRDXFYMM-PPHPATTJSA-N 0.000 description 1
- VXYFARNRGZWHTJ-FVGYRXGTSA-N methyl (2s)-2-amino-3-(4-hydroxyphenyl)propanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VXYFARNRGZWHTJ-FVGYRXGTSA-N 0.000 description 1
- WUKSVVOCYHTIMV-UHFFFAOYSA-N methyl 3-amino-1h-pyrazole-5-carboxylate Chemical compound COC(=O)C=1C=C(N)NN=1 WUKSVVOCYHTIMV-UHFFFAOYSA-N 0.000 description 1
- WKSUKIUHZDWQCZ-UHFFFAOYSA-N methyl 3-amino-1h-pyrazole-5-carboxylate;hydrochloride Chemical compound Cl.COC(=O)C1=CC(N)=NN1 WKSUKIUHZDWQCZ-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- XMZSTQYSBYEENY-RMKNXTFCSA-N n-[4-[(e)-2-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]ethenyl]phenyl]methanesulfonamide Chemical compound C1=C(N2C(NC(=O)C=C2)=O)C=C(C(C)(C)C)C(OC)=C1\C=C\C1=CC=C(NS(C)(=O)=O)C=C1 XMZSTQYSBYEENY-RMKNXTFCSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- AZHVQJLDOFKHPZ-UHFFFAOYSA-N oxathiazine Chemical compound O1SN=CC=C1 AZHVQJLDOFKHPZ-UHFFFAOYSA-N 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- ATYBXHSAIOKLMG-UHFFFAOYSA-N oxepin Chemical compound O1C=CC=CC=C1 ATYBXHSAIOKLMG-UHFFFAOYSA-N 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940002988 pegasys Drugs 0.000 description 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- CTYRPMDGLDAWRQ-UHFFFAOYSA-N phenyl hydrogen sulfate Chemical compound OS(=O)(=O)OC1=CC=CC=C1 CTYRPMDGLDAWRQ-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000128 polypyrrole Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003140 primary amides Chemical class 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- DVUBDHRTVYLIPA-UHFFFAOYSA-N pyrazolo[1,5-a]pyridine Chemical group C1=CC=CN2N=CC=C21 DVUBDHRTVYLIPA-UHFFFAOYSA-N 0.000 description 1
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical compound N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229940053146 rebetol Drugs 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- FGHMGRXAHIXTBM-TWFJNEQDSA-N s-[2-[[(2r,3r,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-(benzylamino)phosphoryl]oxyethyl] 3-hydroxy-2,2-dimethylpropanethioate Chemical compound C([C@@H]1[C@H]([C@@](C)(O)[C@H](N2C3=C(C(NC(N)=N3)=O)N=C2)O1)O)OP(=O)(OCCSC(=O)C(C)(CO)C)NCC1=CC=CC=C1 FGHMGRXAHIXTBM-TWFJNEQDSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003334 secondary amides Chemical class 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- DEKOYVOWOVJMPM-RLHIPHHXSA-N setrobuvir Chemical compound N1([C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(O)=C(C1=O)C=1NC2=CC=C(C=C2S(=O)(=O)N=1)NS(=O)(=O)C)CC1=CC=C(F)C=C1 DEKOYVOWOVJMPM-RLHIPHHXSA-N 0.000 description 1
- VPHXUNBMNWOYNQ-XLBCSPGISA-N setrobuvir Chemical compound N1([C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)/C(C1=O)=C1/NC2=CC=C(C=C2S(=O)(=O)N1)NS(=O)(=O)C)CC1=CC=C(F)C=C1 VPHXUNBMNWOYNQ-XLBCSPGISA-N 0.000 description 1
- 229950004113 setrobuvir Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 description 1
- 229960002063 sofosbuvir Drugs 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000001273 sulfonato group Chemical class [O-]S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229950004886 tegobuvir Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- KHVCOYGKHDJPBZ-WDCZJNDASA-N tetrahydrooxazine Chemical compound OC[C@H]1ONC[C@@H](O)[C@@H]1O KHVCOYGKHDJPBZ-WDCZJNDASA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000004525 thiadiazinyl group Chemical group S1NN=C(C=C1)* 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- JWCVYQRPINPYQJ-UHFFFAOYSA-N thiepane Chemical compound C1CCCSCC1 JWCVYQRPINPYQJ-UHFFFAOYSA-N 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
- VOVUARRWDCVURC-UHFFFAOYSA-N thiirane Chemical compound C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- BQAJJINKFRRSFO-UHFFFAOYSA-N thiolane Chemical compound C1CCSC1.C1CCSC1 BQAJJINKFRRSFO-UHFFFAOYSA-N 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 238000011295 triple combination therapy Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Definitions
- the present invention relates to viral polymerase inhibitors, in particular inhibitors of viral polymerases within the Flaviviridae family such as hepatitis C virus (HCV), processes for their preparation and their use in the treatment of Flaviviridae viral infections such as Hepatitis C virus (HCV) infections.
- HCV hepatitis C virus
- the Flaviviridae are a group of positive single-stranded RNA viruses with a genome size from 9-15 kb.
- the Flaviviridae consist of various genera including: Hepaciviruses (this genus contains only one species, the Hepatitis C virus (HCV), which is composed of many genotypes and subtypes); Flaviviruses (this genus includes the Dengue virus, Japanese Tick-Borne and the Yellow Fever virus and there are some additional Flaviviruses that are unclassified) and Pestiviruses (this genus includes three serotypes of bovine viral diarrhoea virus, but no known human pathogens).
- HCV Hepatitis C virus
- Hepatitis C virus is a major cause of viral hepatitis and has infected more than 200 million people worldwide.
- Hepatitis C virus has a positive-strand RNA genome enclosed in a nucleocapsid and lipid envelope.
- the HCV genome is approximately 9.6 kb in length and encodes a polyprotein of about 3,000 amino acids.
- genotypes 1 a and 1 b account for about 75 % of cases, and genotypes 2 and 3 for 10-20 % of cases. Significant differences are observed in the geographic distribution of HCV genotypes. For example, in Europe genotypes 2 and 3 comprise up to one half of cases whereas genotype 3 is thought to dominate in India.
- varied genotype are observed in the geographic distribution of HCV genotypes.
- HCV chronic bloodborne infection
- HCV pegylated interferon
- SVR sustained viral response
- patients with HCV genotype 1 remain the most difficult to treat, with SVR rates of approximately 40% after 48 weeks of therapy.
- combination peg-IFN/ribavirin therapy is limited by serious side effects, including fatigue, influenza-like symptoms, depression and suicide with peg-I FN, and haemolytic anaemia with ribavirin.
- peg-IFN/ribavirin therapy is contra-indicated in patients who have depression, anaemia, HCV-related decompensated cirrhosis, alcohol/substance abuse and autoimmune disorders or who are pregnant.
- telaprevir Very short-acting antiviral
- boceprevir boceprevir
- Both drugs are protease inhibitors and are approved for the treatment of chronic HCV genotype 1 infection in combination with peg-IFN and ribavirin.
- Pivotal phase 3 trials demonstrated that the addition of telaprevir or boceprevir to peg-IFN/RBV therapy achieved shortened durations of therapy and potent viral suppression, with SVR rates approaching 75% in genotype 1 treatment-naive patients and 30% to 85% in treatment-experienced patients.
- telaprevir is associated with an increased incidence of rash and anaemia
- boceprevir is associated with anaemia and dysgeusia.
- Triple therapy with telaprevir or boceprevir and peg-IFN/ribavirin remains unsuitable for those intolerant to or with contraindications to peg-I FN/ribavirin therapy.
- the HCV genome possesses structural (core) and non-structural (NS2, NS3, NS4A, NS4B, NS5A and NS5B) proteins.
- the non-structural proteins are involved in viral genomic replication, with the initial synthesis of RNA carried out by NS5B RNA dependent RNA polymerase.
- the NS5B protein is a key target for anti-HCV therapy, as it is essential for HCV replication and has no human host equivalent. This protein has been well characterised and is a validated target for drug discovery.
- HCV therapy is also anticipated to evolve towards oral multidrug therapy, in which combinations of different DAA drugs with complementary mechanisms of action serve to increase viral suppression and delay or prevent the emergence of resistance.
- HCV agents particularly with targeted mechanisms of action such as NS5B inhibitors.
- HCV agents with cross-genotypic activity against genotypes 1 , 2 and 3.
- the inventors have found a new class of antiviral compounds, more particularly NS5B polymerase inhibitors, for the treatment of HCV infections.
- Compounds of the present invention are therefore considered to be useful in treating and preventing hepatitis C infections when used on their own or in combination with one or more other antiviral agents such as ribavirin, an antiviral nucleoside, polymerase inhibitor, protease inhibitor and/or inhibitor of viral entry, assembly or egress.
- the combination may also additionally comprise at least one immunomodulatory agent for example an interferon or interferon derivative and/or an inhibitor of inosine-5'-monophosphate dehydrogenase (IMPDH).
- IMPDH inosine-5'-monophosphate dehydrogenase
- compounds of the invention will be efficacious in combination with at least one other DAA with a different mechanism of action and a complementary resistance profile (for example an NS5A inhibitor, a nucleoside or nucleotide NS5B inhibitor or a NS3/4A protease inhibitor) thereby offering an alternative treatment regime for patients not eligible for or treatable with the recently approved triple combination therapy.
- a complementary resistance profile for example an NS5A inhibitor, a nucleoside or nucleotide NS5B inhibitor or a NS3/4A protease inhibitor
- R 1 is H or R a or R 1 together with R 2 and the atoms to which they are attached form an optionally substituted 6-8 membered carbocyclic ring which may be optionally interrupted by one or more heteroatoms independently selected from O, N and S;
- R 2 is H or R b or R 2 together with Ri joins to form an optionally substituted 6-8 membered carbocyclic ring which may be optionally interrupted by one or more heteroatoms independently selected from O, N and S;
- R 3 is an optionally substituted C 3 - 8 cycloalkyl group
- Xi, X 2 and X 3 are each independently selected from N, CH, C-R c and C-A-R 4 provided that at least one of Xi , X 2 and X 3 is C-A-R 4 ;
- A is a covalent bond, -CONH-C(R 5 )(R 6 )-B- or -CONCi-aalkyl-CiRsXReJ-B-;
- R 4 is selected from H, C0 2 H, optionally substituted C0 2 Ci_ 6 alkyl, optionally substituted aryl, optionally substituted arylCi_ 6 alkyl, optionally substituted arylC 2 . 6 alkenyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted heterocyclylC ⁇ alkyl, optionally substituted heteroarylC ⁇ alkyl, optionally substituted heterocyclylC 2 - 6 alkenyl and optionally substituted heteroarylC 2 - 6 alkenyl;
- R 5 and R 6 are each independently selected from H, optionally substituted C ⁇ alkyl, optionally substituted aryl, optionally substituted C ⁇ alkylaryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted C 1 . 6 alkylheterocyclyl and optionally substituted C ⁇ alkylheteroaryl or R 5 and R 6 together with the carbon atom to which they are attached form an optionally substituted C 3 . 6 cycloalkyl group;
- B is a covalent bond or -CONH-R7- where R 7 is selected from optionally substituted aryl, optionally substituted arylCi -6 alkyl, optionally substituted arylC 2 . 6 alkenyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted
- heterocyclylC ⁇ alkyl optionally substituted heteroarylC ⁇ alkyl, optionally substituted heterocyclylC 2 - 6 alkenyl and optionally substituted heteroarylC 2 - 6 alkenyl;
- Z 1 is C or N
- Z 2 , Z 3 , Z 4 and Z 5 are each independently selected from N, CH and C-R d ;
- each R 8 is independently selected from H and C 1 . 6 alkyl and each alkyl, alkenyl, alkynyl, cycloalkyi, aryl, heterocyclyl and heteroaryl in the definition of R a , R b , R c and R d may be optionally substituted;
- each heterocyclyl or heteroaryl has 1 , 2, 3 or 4 heteroatoms independently selected from O, S and N.
- C-A-R 4 is not C-H.
- ⁇ , X' 2 and X' 3 are each independently selected from N, CH, C-R c , C-A-R' 4 provided that at least one of ⁇ , X' 2 and X' 3 is C-A-R' 4 wherein R' 4 is C0 2 H or COaC ⁇ alkyl; and
- Ri, R2, R3, R5, R6, R7, C-R c , Zi, Z 2 , Z 3 , Z 4 and Z 5 are as defined above.
- the compounds of formula (I) are inhibitors of HCV.
- the compounds of formula (I) inhibit RNA synthesis by the RNA dependent RNA polymerase of HCV (the NS5B protein encoded by HCV).
- NS5B polymerase inhibitors have been clinically validated as potential antiviral agents for the treatment of HCV infection.
- a pharmaceutical agent comprising the compound of formula (I) defined above and pharmaceutically acceptable salts, N-oxides, solvates, hydrates, racemates, enantiomers and isomers thereof.
- the pharmaceutical agent may be an antiviral agent.
- a viral polymerase inhibitor in particular a HCV polymerase inhibitor such as a NS5B polymerase inhibitor comprising the compound of formula (I) defined above and pharmaceutically acceptable salts, N-oxides, solvates, hydrates, racemates, enantiomers and isomers thereof.
- the compound of formula (I ) and pharmaceutically acceptable salts, N-oxides, solvates, hydrates, racemates, enantiomers and isomers thereof may be administered in the form of a pharmaceutical composition together with a pharmaceutically acceptable carrier.
- a pharmaceutical composition comprising the compound of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates, hydrates, racemates, enantiomers and isomers thereof and a pharmaceutically acceptable carrier.
- the pharmaceutical composition additionally comprises a therapeutically effective amount of one or more antiviral agents such as at least one other anti-HCV agent.
- a method for the treatment of a Flaviviridae viral infection such as a HCV infection which comprises administering an effective amount of the compound of formula (I) and pharmaceutically acceptable salts, W-oxides, solvates, hydrates, racemates, enantiomers and isomers thereof or the pharmaceutical composition defined above to a subject diagnosed with, suffering from or at risk of developing said viral infection.
- a method of inhibiting the RNA-dependent RNA polymerase activity of the enzyme NS5B, encoded by HCV comprising exposing the enzyme NS5B to an effective amount of the compound of formula (I) defined above and pharmaceutically acceptable salts, W-oxides, solvates, hydrates, racemates, enantiomers and isomers thereof.
- a method of inhibiting HCV replication comprising exposing a cell infected with HCV to an effective amount of the compound of formula (I) defined above and pharmaceutically acceptable salts, W-oxides, solvates, hydrates, racemates, enantiomers and isomers thereof.
- the present invention relates to compounds of formula (I) which inhibit viral polymerases and are useful in the treatment of Flaviviridae viral infections, particularly, hepatitis C (HCV).
- HCV hepatitis C
- the present invention relates to compounds of formula I, salts, N-oxides, racemates, enantiomers and isomers thereof as defined above.
- R 1 is H or d- 6 alkyl, preferably methyl, ethyl or propyl, more preferably H or methyl and R 2 is H or R b , preferably H.
- R 1 together with R 2 joins to form an optionally substituted 6-8 membered carbocyclic ring which may be optionally interrupted by one or more heteroatoms independently selected from O, N and S.
- R 1 together with R 2 joins to form a 7- membered carbocycle.
- R 2 together are a divalent linking moiety selected from the group consisting of -CH 2 CH 2 CH 2 -; -OCH 2 CH 2 -; -CH 2 OCH 2 -; - CH 2 CH 2 0-; -NCH 2 CH 2 -; -CH 2 NCH 2 -; and -CH 2 CH 2 N-, thereby joining to form a 7- membered carbocyclic ring together with the atoms to which R 1 and R 2 are attached the carbocyclic ring being optionally interrupted by O or N, preferably O.
- R 2 together are a divalent linking moiety of formula - CH 2 CH 2 0-.
- R 3 is an optionally substituted C 3 . 6 cycloalkyl group, preferably cyclohexyl.
- A is a covalent bond and R 4 is C0 2 H or optionally substituted C0 2 Ci_ 6 alkyl.
- X 2 and X 3 are each independently selected from N, CH, C-R c or C-A-R 4 provided that at least one of Xi , X 2 and X 3 is C-A-R 4 and A is a covalent bond and R 4 is C0 2 H or optionally substituted C0 2 C 1 . 6 alkyl.
- X 1 is C-A-R 4 ;
- X 2 and X 3 are each independently selected from N, CH or C-R c preferably N or CH.
- X 2 is C-A-R 4 and X 1 and X 3 are each independently selected from N, CH or C-R c preferably N or CH.
- X 3 is C-A-R 4 and X 1 and X 2 are each independently selected from N, CH or C-R c preferably N or CH.
- R 4 is selected from H, C0 2 H and optionally substituted CO ⁇ . 6 alkyl.
- R 4 is C0 2 H or CC ⁇ C ⁇ al yl, preferably C0 2 H or CO ⁇ . 3 alkyl, more preferably R 4 is selected from C0 2 H, C0 2 CH 3 and C0 2 CH 2 CH 3 .
- A is a covalent bond
- A is -CONH-C(R 5 )(R 6 )-B- wherein R 5 and R 6 are each independently selected from H, C ⁇ alkyl (preferably C ⁇ alkyl, more preferably methyl), C ⁇ 6 alkylaryl (preferably optionally substituted benzyl); C ⁇ alkylheterocyclyl and Ci_
- alkylheteroaryl preferably CH 2 heteroaryl, wherein the heteroaryl is preferably a 5-, 6- or 9- membered heteroaryl, more preferably a 5-, 6- or 9-membered N-containing heteroaryl
- R 5 and R 6 together with the carbon atom to which they are attached form a cyclobutyl group.
- B is a covalent bond
- B is -CONHR 7 - wherein R 7 is selected from aryl (preferably phenyl), arylC ⁇ alkyl (preferably phenylC ⁇ alkyl) and arylC 2 - 6 alkenyl (preferably phenylC 2 _ 3 alkenyl).
- R 7 is phenylethenyl.
- the compound of formula (I) is a compound of formula (la)
- Z 3 is CH or C-R d and Ri , R 2 , R 3 , R d , X 2 and X 3 are as previously defined and salts, A/-oxides, solvates, hydrates, racemates, enantiomers and isomers thereof.
- R d is selected from the group consisting of halo, OH, d_ 3 alkoxy or d_ 3 alkoxyaryl wherein the aryl is unsubstituted or substituted with heterocyclyl (preferably 5 or 6 membered heterocyclyl containing N such as morpholine or pyrrolidinone).
- heterocyclyl preferably 5 or 6 membered heterocyclyl containing N such as morpholine or pyrrolidinone.
- F, OH, OCH 3 and optionally substituted benzyloxy including unsubstituted benzyloxy and 2-(morpholin-4-yl)-5-(2-oxopyrrolidin-1 -yl)benzyloxy are particularly preferred R d groups when Z 3 is C-R d .
- R ⁇ R 2 , R3, Z 3 ⁇ , X 2 and X 3 are as previously defined and salts, N-oxides, solvates, hydrates, racemates, enantiomers and isomers thereof.
- A, R 2 , R3, R4, Z ⁇ X ⁇ , X2 and X 3 are as previously defined provided that A- R 4 is not H (i.e. where A is a covalent bond and R 4 is H) and salts, N-oxides, solvates, hydrates, racemates, enantiomers and isomers thereof
- C h alky refers to optionally substituted straight chain or branched chain hydrocarbon groups having from 1 to 6 carbon atoms. Examples include methyl (Me), ethyl (Et), propyl (Pr), isopropyl (/-Pr), butyl (Bu), isobutyl (/-Bu), sec-butyl (s-Bu), tert-butyl (f-Bu), pentyl, neopentyl, hexyl and the like. Unless the context requires otherwise, the term “d. 6 alkyl” also encompasses alkyl groups containing one less hydrogen atom such that the group is attached via two positions i.e. divalent. and "C 1 .
- alkyl including methyl, ethyl, propyl, /sopropyl, n-butyl, / ' so-butyl, sec-butyl and ferf-butyl are preferred with methyl being particularly preferred.
- C 2 - 6 alkenyl refers to optionally substituted straight chain or branched chain hydrocarbon groups having at least one double bond of either E or Z stereochemistry where applicable and 2 to 6 carbon atoms. Examples include vinyl, 1 -propenyl, 1- and 2- butenyl and 2-methyl-2-propenyl. Unless the context requires otherwise, the term "C 2 .
- alkenyl also encompasses alkenyl groups containing one less hydrogen atom such that the group is attached via two positions i.e. divalent.
- C 2 - 4 alkenyl and “C 2 _ 3 alkenyl” including ethenyl, propenyl and butenyl are preferred with ethenyl being particularly preferred.
- C 2 - 6 alkynyl refers to optionally substituted straight chain or branched chain hydrocarbon groups having at least one triple bond and 2 to 6 carbon atoms.
- C 2 - 6 alkynyl also encompasses alkynyl groups containing one less hydrogen atom such that the group is attached via two positions i.e. divalent.
- C 2 . 3 alkynyl is preferred.
- C 3 . 8 cycloalkyl refers to non-aromatic cyclic groups having from 3 to 8 carbon atoms, including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. It will be understood that cycloalkyl groups may be saturated such as cyclohexyl or unsaturated such as cyclohexenyl.
- C 3 . 6 cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl are preferred.
- hydroxy and "hydroxyl” refer to the group -OH.
- Ci_ 6 alkoxy refers to an alkyl group as defined above covalently bound via an O linkage containing 1 to 6 carbon atoms, such as methoxy, ethoxy, propoxy, isoproxy, butoxy, tert-butoxy and pentoxy.
- C 1 . 4 alkoxy and “C ⁇ alkoxy” including methoxy, ethoxy, propoxy and butoxy are preferred with methoxy being particularly preferred.
- Ci_ 6 alkylhalo refers to a Ci_ 6 alkyl which is substituted with one or more halogens. d. 3 alkylhalo groups are preferred, such as for example, -CHF 2 and -CF 3 .
- Ci_ 6 alkoxylhalo refers to a C ⁇ alkoxyl which is substituted with one or more halogens. d- 3 alkoxylhalo groups are preferred, such as for example, -OCHF 2 and - OCF 3 .
- carboxylate or “carboxyl” refers to the group -COO " or -COOH.
- esters refers to a carboxyl group having the hydrogen replaced with, for example a C ⁇ alkyl group (“carboxylCi. 6 alkyl” or “alkylester”), an aryl or aralkyl group (“arylester” or “aralkylester”) and so on.
- C0 2 Ci_ 3 alkyl groups are preferred, such as for example, methylester (CO 2 Me), ethylester (C0 2 Et) and propylester (C0 2 Pr) and includes reverse esters thereof (e.g. -OCOMe, -OCOEt and -OCOPr).
- cyano refers to the group -CN.
- nitro refers to the group -N0 2 .
- amino refers to the group -NH 2 .
- substituted amino or “secondary amino” refers to an amino group having a hydrogen replaced with, for example a C ⁇ alkyl group (“C ⁇ alkylamino”), an aryl or aralkyl group (“arylamino", “aralkylamino”) and so on.
- C ⁇ alkylamino groups are preferred, such as for example, methylamino (NHMe), ethylamino (NHEt) and propylam ino (NHPr).
- disubstituted amino or "tertiary amino” refers to an amino group having the two hydrogens replaced with, for example a C ⁇ alkyl group, which may be the same or different (“dialkylamino"), an aryl and alkyl group (“aryl(alkyl)amino”) and so on.
- D ' ⁇ (C ⁇ .
- 3 alkyl)amino groups are preferred, such as for example, dimethylamino (NMe 2 ), diethylamino (NEt 2 ), dipropylamino (NPr 2 ) and variations thereof (e.g. N(Me)(Et) and so on).
- NMe 2 dimethylamino
- NEt 2 diethylamino
- NPr 2 dipropylamino
- variations thereof e.g. N(Me)(Et) and so on.
- substituted acyl or “ketone” refers to an acyl group having a hydrogen replaced with, for example a C ⁇ alkyl group ("Ci. 6 alkylacyl” or “alkylketone” or “ketoalkyl”), an aryl group (“arylketone”), an aralkyl group (“aralkylketone) and so on. Ci_ 3 alkylacyl groups are preferred.
- aminoacyl refers to the group -NHC(0)H.
- substituted amido or “substituted amide” refers to an amido group having a hydrogen replaced with, for example a C ⁇ alkyl group ("Ci_ 6 alkylamido” or “Ci_ 6 alkylam ide”), an aryl (“arylamido”), aralkyl group (“aralkylamido”) and so on.
- C ⁇ alkylamide groups are preferred, such as for example, methylamide (-C(O)NHMe), ethylamide (- C(O)NHEt) and propylamide (-C(O)NHPr) and includes reverse amides thereof (e.g. - NHMeC(O)-, -NHEtC(O)- and -NHPrC(O)-).
- disubstituted amido or “disubstituted amide” refers to an amido group having the two hydrogens replaced with, for example a Ci_ 6 alkyl group ("d C ⁇ ealky amido” or “diiC ⁇ ealkylJamide”), an aralkyl and alkyl group ("alkyl(aralkyl)am ido") and so on.
- Di(d. 3 alkyl)amide groups are preferred, such as for example, dimethylamide (-C(0)NMe 2 ), diethylamide (-C(0)NEt 2 ) and dipropylamide ((-C(0)NPr 2 ) and variations thereof (e.g. - C(0)N(Me)Et and so on) and includes reverse amides thereof.
- thiol refers to the group -SH.
- Ci_ 6 alkylthio refers to a thiol group having the hydrogen replaced with a Ci- 6 alkyl group.
- Ci_ 3 alkylthio groups are preferred, such as for example, thiolmethyl, thiolethyl and thiolpropyl.
- substituted sulfinyl or “sulfoxide” refers to a sulfinyl group having the hydrogen replaced with, for example a C ⁇ alkyl group ("C ⁇ alkylsulfinyl” or "Ci_
- alkylsulfoxide an aryl (“arylsulfinyl”), an aralkyl (“aralkyl sulfinyl”) and so on.
- d_ 3 alkylsulf inyl groups are preferred, such as for example, -SOmethyl, -SOethyl and - SOpropyl.
- sulfonyl refers to the group -S0 2 H.
- substituted sulfonyl refers to a sulfonyl group having the hydrogen replaced with, for example a C ⁇ alkyl group (“sulfonylC ⁇ ealkyl”), an aryl (“arylsulfonyl”), an aralkyl (“aralkylsulfonyl”) and so on.
- SulfonylC ⁇ alkyl groups are preferred, such as for example, -S0 2 Me, -S0 2 Et and -S0 2 Pr.
- sulfonylamido or "sulfonamide” refers to the group -S0 2 NH 2 .
- substituted sulfonamido or “substituted sulphonamide” refers to an sulfonylamido group having a hydrogen replaced with, for example a C ⁇ alkyl group
- SulfonylamidoCi. 6 alkyl an aryl (“arylsulfonamide”), aralkyl (“aralkylsulfonamide”) and so on.
- SulfonylamidoC ⁇ alkyl groups are preferred, such as for example, -S0 2 NHMe, - S0 2 NHEt and -S0 2 NHPr and includes reverse sulfonamides thereof (e.g. -NHS0 2 Me, - NHS0 2 Et and -NHS0 2 Pr).
- disubstituted sufonamido or “disubstituted sulphonamide” refers to an sulfonylamido group having the two hydrogens replaced with, for example a C ⁇ alkyl group, which may be the same or different ("sulfonylamidodi(C 1 . 6 alkyl)"), an aralkyl and alkyl group ("sulfonamido(aralkyl)alkyl”) and so on.
- Sulfonylamidod C ⁇ alkyl) groups are preferred, such as for example, -S0 2 NMe 2 , -S0 2 NEt 2 and -S0 2 NPr 2 and variations thereof (e.g. - S0 2 N(Me)Et and so on) and includes reserve sulfonamides thereof.
- sulfate refers to the group OS(0) 2 OH and includes groups having the hydrogen replaced with, for example a C 1 . 6 alkyl group ("alkylsulfates”), an aryl (“arylsulfate”), an aralkyl (“aralkylsulfate”) and so on. ( ⁇ sulfates are preferred, such as for example, OS(0) 2 OMe, OS(0) 2 OEt and OS(0) 2 OPr.
- sulfonate refers to the group S0 3 H and includes groups having the hydrogen replaced with, for example a C 1 . 6 alkyl group (“alkylsulfonate”), an aryl
- arylsulfonate an aralkyl
- aralkylsulfonate an aralkyl
- aryl refers to a carbocyclic (non-heterocyclic) aromatic ring or mono-, bi- or tri-cyclic ring system.
- the aromatic ring or ring system is generally composed of 6 to 10 carbon atoms.
- aryl groups include but are not limited to phenyl, biphenyl, naphthyl and tetrahydronaphthyl. 6-membered aryls such as phenyl are preferred.
- alkylaryl refers to C ⁇ alkylaryl such as benzyl.
- alkoxyaryl refers to Ci_
- 6alkyloxyaryl such as benzyloxy.
- heterocyclyl refers to a moiety obtained by removing a hydrogen atom from a ring atom of a heterocyclic compound which moiety has from 3 to 10 ring atoms (unless otherwise specified), of which 1 , 2, 3 or 4 are ring heteroatoms each heteroatom being independently selected from O, S and N.
- the prefixes 3-, 4-, 5-, 6-, 7-, 8-, 9- and 10- membered denote the number of ring atoms, or range of ring atoms, whether carbon atoms or heteroatoms.
- the term "3-10 membered heterocylyl”, as used herein, pertains to a heterocyclyl group having 3, 4, 5, 6, 7, 8, 9 or 10 ring atoms.
- heterocylyl groups include 5- 6-membered monocyclic heterocyclyls and 9-10 membered fused bicyclic heterocyclyls.
- Examples of monocyclic heterocyclyl groups include, but are not limited to, those containing one nitrogen atom such as aziridine (3-membered ring), azetidine (4-membered ring), pyrrolidine (tetrahydropyrrole), pyrroline (e.g., 3-pyrroline, 2,5-dihydropyrrole), 2H- pyrrole or 3H-pyrrole (isopyrrole, isoazole) or pyrrolidinone (5-membered rings) , piperidine, dihydropyridine, tetrahydropyridine (6-membered rings), and azepine (7-membered ring); those containing two nitrogen atoms such as imidazoline, pyrazolidine (diazolidine), imidazoline, pyrazoline (dihydropyrazole) (5-membered rings), piperazine (6-membered ring); those containing one oxygen atom such as oxirane (3-membered
- Heterocyclyls also encompass aromatic heterocyclyls and non-aromatic heterocyclyls. Such groups may be substituted or unsubstituted.
- aromatic heterocyclyl may be used interchangeably with the term “heteroaromatic” or the term “heteroaryl” or “hetaryl”.
- the heteroatoms in the aromatic heterocyclyl group may be independently selected from N, S and O.
- Heteroaryl is used herein to denote a heterocyclic group having aromatic character and embraces aromatic monocyclic ring systems and polycyclic (e.g. bicyclic) ring systems containing one or more aromatic rings.
- aromatic heterocyclyl also encompasses pseudoaromatic heterocyclyls.
- aromatic heterocyclyl refers to a ring system which is not strictly aromatic, but which is stabilized by means of delocalization of electrons and behaves in a similar manner to aromatic rings.
- aromatic heterocyclyl therefore covers polycyclic ring systems in which all of the fused rings are aromatic as well as ring systems where one or more rings are non-aromatic, provided that at least one ring is aromatic. In polycyclic systems containing both aromatic and non-aromatic rings fused together, the group may be attached to another moiety by the aromatic ring or by a non- aromatic ring.
- heteroaryl groups are monocyclic and bicyclic groups containing from five to ten ring members.
- the heteroaryl group can be, for example, a five membered or six membered monocyclic ring or a bicyclic structure formed from fused five and six membered rings or two fused six membered rings or two fused five membered rings.
- Each ring may contain up to about four heteroatoms typically selected from nitrogen, sulphur and oxygen.
- the heteroaryl ring will contain up to 4 heteroatoms, more typically up to 3 heteroatoms, more usually up to 2, for example a single heteroatom.
- the heteroaryl ring contains at least one ring nitrogen atom.
- the nitrogen atoms in the heteroaryl rings can be basic, as in the case of an imidazole or pyridine, or essentially non-basic as in the case of an indole or pyrrole nitrogen.
- the number of basic nitrogen atoms present in the heteroaryl group, including any amino group substituents of the ring, will be less than five.
- Aromatic heterocyclyl groups may be 5-membered or 6-membered mono-cyclic aromatic ring systems.
- 5-membered monocyclic heteroaryl groups include but are not limited to furanyl, thienyl, pyrrolyl, oxazolyl, oxadiazolyl (including 1 ,2,3 and 1 ,2,4 oxadiazolyls and furazanyl i.e.
- thiazolyl isoxazolyl, isothiazolyl, pyrazolyl, imidazolyl, triazolyl (including 1 ,2,3, 1 ,2,4 and 1 ,3,4 triazolyls), oxatriazolyl, tetrazolyl, thiadiazolyl (including 1 ,2,3 and 1 ,3,4 thiadiazolyls) and the like.
- 6-membered monocyclic heteroaryl groups include but are not limited to pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, pyranyl, oxazinyl, dioxinyl, thiazinyl, thiadiazinyl and the like.
- 6-membered aromatic heterocyclyls containing nitrogen include pyridyl (1 nitrogen), pyrazinyl, pyrimidinyl and pyridazinyl (2 nitrogens).
- Aromatic heterocyclyl groups may also be bicyclic or polycyclic heteroaromatic ring systems such as fused ring systems (including purine, pteridinyl, napthyridinyl, 1 H thieno[2,3-c]pyrazolyl, thieno[2,3-b]furyl and the like) or linked ring systems (such as oligothiophene, polypyrrole and the like).
- fused ring systems including purine, pteridinyl, napthyridinyl, 1 H thieno[2,3-c]pyrazolyl, thieno[2,3-b]furyl and the like
- linked ring systems such as oligothiophene, polypyrrole and the like.
- Fused ring systems may also include aromatic 5- membered or 6-membered heterocyclyls fused to carbocyclic aromatic rings such as phenyl, napthyl, indenyl, azulenyl, fluorenyl, anthracenyl and the like, such as 5-membered aromatic heterocyclyls containing nitrogen fused to phenyl rings, 5-membered aromatic heterocyclyls containing 1 or 2 nitrogens fused to phenyl ring.
- aromatic 5- membered or 6-membered heterocyclyls fused to carbocyclic aromatic rings such as phenyl, napthyl, indenyl, azulenyl, fluorenyl, anthracenyl and the like, such as 5-membered aromatic heterocyclyls containing nitrogen fused to phenyl rings, 5-membered aromatic heterocyclyls containing 1 or 2 nitrogens fused to phenyl ring.
- a bicyclic heteroaryl group may be, for example, a group selected from: a) a benzene ring fused to a 5- or 6-membered ring containing 1 , 2 or 3 ring heteroatoms; b) a pyridine ring fused to a 5- or 6-membered ring containing 1 , 2 or 3 ring heteroatoms; c) a pyrimidine ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; d) a pyrrole ring fused to a 5- or 6-membered ring containing 1 , 2 or 3 ring heteroatoms; e) a pyrazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; f) an imidazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; g) an oxazole ring fused to a 5-
- bicyclic heteroaryl groups containing a five membered ring fused to another five membered ring include but are not limited to imidazothiazole (e.g. imidazo[2, 1-b]thiazole) and imidazoimidazole (e.g. imidazo[1 ,2-a]imidazole).
- imidazothiazole e.g. imidazo[2, 1-b]thiazole
- imidazoimidazole e.g. imidazo[1 ,2-a]imidazole
- bicyclic heteroaryl groups containing a six membered ring fused to a five membered ring include but are not limited to benzofuran, benzothiophene, benzimidazole, benzoxazole, isobenzoxazole, benzisoxazole, benzothiazole,
- benzisothiazole isobenzofuran, indole, isoindole, indolizine, indoline, isoindoline, purine (e.g., adenine, guanine), indazole, pyrazolopyrimidine (e.g. pyrazolo[1 ,5-a]pyrimidine), benzodioxole and pyrazolopyridine (e.g. pyrazolo[1 ,5-a]pyridine) groups.
- a further example of a six membered ring fused to a five membered ring is a pyrrolopyridine group such as a pyrrolo[2,3-b]pyridine group.
- bicyclic heteroaryl groups containing two fused six membered rings include but are not limited to quinoline, isoquinoline, chroman, thiochroman, chromene, isochromene, isochroman, benzodioxan, quinolizine, benzoxazine, benzodiazine, pyridopyridine, quinoxaline, quinazoline, cinnoline, phthalazine, naphthyridine and pteridine groups.
- heteroaryl groups containing an aromatic ring and a non-aromatic ring include tetrahydronaphthalene, tetrahydroisoquinoline, tetrahydroquinoline,
- aromatic heterocyclyls fused to carbocyclic aromatic rings may therefore include but are not limited to benzothiophenyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzimidazolyl, indazolyl, benzoxazolyl, benzisoxazolyl, isobenzoxazoyi, benzothiazolyl, benzisothiazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, benzotriazinyl, phthalazinyl, carbolinyl and the like.
- non-aromatic heterocyclyl encompasses optionally substituted saturated and unsaturated rings which contain at least one heteroatom selected from the group consisting of N, S and O.
- Non-aromatic heterocyclyls may be 3-7 membered mono-cyclic rings.
- Examples of 5-membered non-aromatic heterocyclyl rings include 2H-pyrrolyl, 1 - pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, 1 -pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrazolinyl, 2-pyrazolinyl, 3-pyrazolinyl, pyrazolidinyl, 2-pyrazolidinyl, 3-pyrazolidinyl, imidazolidinyl, 3-dioxalanyl, thiazolidinyl, isoxazolidinyl, 2-imidazolinyl and the like.
- 6-membered non-aromatic heterocyclyls include piperidinyl, piperidinonyl, pyranyl, dihyrdopyranyl, tetrahydropyranyl, 2H pyranyl, 4H pyranyl, thianyl, thianyl oxide, thianyl dioxide, piperazinyl, diozanyl, 1 ,4-dioxinyl, 1 ,4-dithianyl, 1 ,3,5- triozalanyl, 1 ,3,5-trithianyl, 1 ,4-morpholinyl, thiomorpholinyl, 1 ,4-oxathianyl, triazinyl, 1 ,4- thiazinyl and the like.
- Examples of 7-membered non-aromatic heterocyclyls include azepanyl, oxepanyl, thiepanyl and the like.
- Non-aromatic heterocyclyl rings may also be bicyclic heterocyclyl rings such as linked ring systems (for example uridinyl and the like) or fused ring systems.
- Fused ring systems include non-aromatic 5-membered, 6-membered or 7-membered heterocyclyls fused to carbocyclic aromatic rings such as phenyl, napthyl, indenyl, azulenyl, fluorenyl, anthracenyl and the like.
- Examples of non-aromatic 5-membered, 6-membered or 7- membered heterocyclyls fused to carbocyclic aromatic rings include indolinyl,
- halo refers to fluoro, chloro, bromo or iodo.
- the term "optionally substituted” or “optional substituent” as used herein refers to a group which may or may not be further substituted with 1 , 2, 3, 4 or more groups, preferably 1 , 2 or 3, more preferably 1 or 2 groups selected from the group consisting of Chalky!, C 2 - 6 alkenyl, C 2 - 6 alkynyl, C 3 .
- suitable derivatives of aromatic heterocyclyls containing nitrogen include W-oxides thereof.
- the compounds of the invention may also be prepared as salts which are pharmaceutically acceptable, but it will be appreciated that non-pharmaceutically acceptable salts also fall within the scope of the present invention, since these are useful as
- pharmaceutically acceptable salts include salts of pharmaceutically acceptable cations such as sodium , potassium, lithium, calcium, magnesium, ammonium and alkylamimonium; acid addition salts of pharmaceutically acceptable inorganic acids such as hydrochloric, orthophosphoric, sulfuric, phosphoric, nitric, carbonic, boric, sulfamic and hydrobromic acids; or salts of pharmaceutically acceptable organic acids such as acetic, propionic, butyric, tartaric, maleic, hydroxymaleic, fumaric, citric, lactic, mucic, gluconic, benzoic, succinic, oxalic, phenylacetic, methanesulfonic, trihalomethanesulfonic, toluenesulfonic,
- Salts of amine groups may also comprise quaternary ammonium salts in which the amino nitrogen atom carries a suitable organic group such as an alkyl, alkenyl, alkynyl or aralkyl moiety.
- the salts may be formed by conventional means, such as by reacting the free base form of the compound with one or more equivalents of the appropriate acid.
- a reference to a pharmaceutically acceptable salt includes the solvent addition forms or crystal forms thereof, particularly solvates or polymorphs.
- Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and may be formed during the process of crystallization with pharmaceutically acceptable solvents such as water, alcohols such as methanol, ethanol or isopropyl alcohol, DMSO, acetonitrile, dimethyl formamide (DMF) and the like with the solvate forming part of the crystal lattice by either non-covalent binding or by occupying a hole in the crystal lattice. Hydrates are formed when the solvent is water, alcoholates are formed when the solvent is alcohol.
- Solvates of the compounds of the present invention can be conveniently prepared or formed during the processes described herein.
- the compounds of the present invention can exist in unsolvated as well as solvated forms.
- the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.
- the compounds of the present invention can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like.
- pharmaceutically acceptable solvents such as water, ethanol, and the like.
- the solvated forms of the compounds of the present invention are also considered to be disclosed herein.
- compounds of formula (I) may possess a chiral centre and may therefore exist as an isomer such as a racemate or an R- or S- enantiomer.
- the compounds may therefore be used as a purified enantiomer or diastereomer, or as a mixture of any ratio thereof.
- the isomers may be separated conventionally by chromatographic methods or using a resolving agent. Alternatively the individual isomers may be prepared by asymmetric synthesis using chiral intermediates. Where the compound has a carbon- carbon double bond, it may occur in Z- or E- form and all isomeric forms of the compounds being included in the present invention.
- This invention also encompasses prodrugs of the compounds of formula (I).
- pro-drug is used herein in its broadest sense to include those compounds which are converted in vivo to the compound of formula (I).
- Use of the prodrug strategy optimises the delivery of the drug to its site of action.
- the compounds of formula (I) having carboxylic esters may act as prodrug moieties with respect to their corresponding carboxylic acid analogues.
- RNA dependent RNA polymerase of HCV RNA dependent RNA polymerase of HCV
- HCV NS5B polymerase which is the viral RNA-dependent RNA polymerase (RdRp) that is responsible for viral replications.
- RdRp viral RNA-dependent RNA polymerase
- HCV NS5B protein is released from a polyprotein and is involved in the synthesis of double-stranded RNA from a single-stranded viral RNA genome. It is believed that the replication and/or reproduction of HCV virus may be inhibited or prevented through the inhibition of NS5B polymerase and suppress or prevent the formation of the double- stranded HCV RNA.
- the compounds of formula (I) act by specific inhibition of NS5B polymerase, the compounds may be tested for the lack of inhibitory activity in an assay measuring the activity of an RNA-dependent RNA polymerase other than HCV polymerase or in a DNA dependent RNA polymerase assay.
- the invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier.
- the pharmaceutical composition may further comprise or be administered in combination with one or more other antiviral agents such as Ribavirin (Copegus® or Rebetol®), an antiviral nucleoside inhibitor of NS5B polymerase (such as 4-amino-7-(2-C-methyl- -D-ribofuranosyl)-pyrrolo[2, 1-f][1 ,2,4]triazine; PSI-7977; PSI-938; RG7128 or mericitabine; IDX-184; INX-189 and other such agents that may be developed) a non-nucleoside inhibitor of NS5B polymerase (such as GS-9190 or tegobuvir; PF-868554 or filibuvir; VX-222; IDX-375; ABT-072; ABT-333; ANA-598 or setrobuvir;
- the composition may also additionally comprise at least one immunomodulatory agent for example an interferon or interferon derivative such as interferon alpha 2B (such as Intron® A interferon available from Schering Corp., Kenilworth, N.J.), pegylated interferon alpha 2A (such as Pegasys® available from Hoffmann-LaRoche, Nutley, N.J.), pegylated interferon alpha 2B (such as Peg-lntron® available from Schering Corp.
- interferon alpha 2B such as Intron® A interferon available from Schering Corp., Kenilworth, N.J.
- pegylated interferon alpha 2A such as Pegasys® available from Hoffmann-LaRoche, Nutley, N.J.
- pegylated interferon alpha 2B such as Peg-lntron® available from Schering Corp.
- the other antiviral agent is Ribavarin optionally in combination with peg/I FN.
- the other antiviral agent is an NS5B inhibitor, more particularly a nucleoside inhibitor such as the bicyclic nucleosides and nucleotides of the general formula described in WO2010/002877, for example, 4-amino-7-(2-C-methyl-3-D- ribofuranosyl)-pyrrolo[2, 1-f][1 ,2,4]triazine.
- the other antiviral agent is an NS3/4A protease inhibitor such as telaprevir (VX-950) or Incivek®; boceprevir or Victrelis®; BI-201335; TMC-435; RG- 7227 or danoprevir; MK-7009 or vaniprevir; GS-9451 ; GS-9256; BMS-650032; ACH-1625; ACH-2684; MK-5172; ABT-450; IDX-320; SCH-900518, particularly telaprevir (VX-950).
- VX-950 NS3/4A protease inhibitor
- the other antiviral agent is an NS5A inhibitor such as BMS-790052 (daclatasvir); GS-5885; ABT-267; PPI-461 ; ACH-2928; GSK2336805, particularly BMS-790052 (daclatasvir).
- composition is intended to include the formulation of an active ingredient with conventional carriers and excipients, and also with encapsulating materials as the carrier, to give a capsule in which the active ingredient (with or without other carriers) is surrounded by the encapsulation carrier.
- Any carrier must be “pharmaceutically acceptable” meaning that it is compatible with the other ingredients of the composition and is not deleterious to a subject.
- compositions of the present invention may contain other therapeutic agents as described above, and may be formulated, for example, by employing conventional solid or liquid vehicles or diluents, as well as pharmaceutical additives of a type appropriate to the mode of desired administration (for example, excipients, binders, preservatives, stabilizers, flavours, etc.) according to techniques such as those well known in the art of pharmaceutical formulation (See, for example, Remington: The Science and Practice of Pharmacy, 21st Ed. , 2005, Lippincott Williams & Wilkins).
- the pharmaceutical composition includes those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, sub-cutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation.
- compositions and unit dosages thereof may thus be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration ; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use.
- Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
- pharmaceutically acceptable carriers can be either solid or liquid.
- Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispensable granules.
- a solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilisers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
- Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium
- carboxymethylcellulose a low melting wax, cocoa butter, and the like.
- preparation is intended to include the formulation of the active compound with
- encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it.
- a carrier which is thus in association with it.
- cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.
- Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water-propylene glycol solutions.
- parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.
- Sterile liquid form compositions include sterile solutions, suspensions, emulsions, syrups and elixirs.
- the active ingredient can be dissolved or suspended in a
- pharmaceutically acceptable carrier such as sterile water, sterile organic solvent or a mixture of both.
- compositions according to the present invention may thus be formulated for parenteral administration (e. g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative.
- the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulation agents such as suspending, stabilising and/or dispersing agents.
- the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
- compositions suitable for injectable use include sterile injectable solutions or dispersions, and sterile powders for the extemporaneous preparation of sterile injectable solutions. They should be stable under the conditions of manufacture and storage and may be preserved against oxidation and the contaminating action of microorganisms such as bacteria or fungi.
- the solvent or dispersion medium for the injectable solution or dispersion may contain any of the conventional solvent or carrier systems for the compounds, and may contain, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
- polyol for example, glycerol, propylene glycol and liquid polyethylene glycol, and the like
- compositions suitable for injectable use may be delivered by any appropriate route including intravenous, intramuscular, intracerebral, intrathecal, epidural injection or infusion.
- Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various other ingredients such as these enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the various sterilised active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- preferred methods of preparation are vacuum drying or freeze-drying of a previously sterile-filtered solution of the active ingredient plus any additional desired ingredients.
- the active ingredients When the active ingredients are suitably protected they may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsule, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet.
- the active compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
- the amount of active compound in therapeutically useful compositions should be sufficient that a suitable dosage will be obtained.
- the tablets, troches, pills, capsules and the like may also contain the components as listed hereafter: a binder such as gum, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such a sucrose, lactose or saccharin may be added or a flavouring agent such as peppermint, oil of wintergreen, or cherry flavouring.
- a binder such as gum, acacia, corn starch or gelatin
- excipients such as dicalcium phosphate
- a disintegrating agent such as corn starch, potato starch, alginic acid and the like
- a lubricant such as magnesium stearate
- a sweetening agent such as sucrose, lactose or saccharin may be added or a flavouring agent such as peppermint, oil of winter
- tablets, pills, or capsules may be coated with shellac, sugar or both.
- a syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavouring such as cherry or orange flavour.
- any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed.
- the active compound (s) may be incorporated into sustained-release preparations and formulations, including those that allow specific delivery of the active peptide to specific regions of the gut.
- Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilising and thickening agents, as desired.
- Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.
- Pharmaceutically acceptable carriers and/or diluents include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
- solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for oral administration.
- liquid forms include solutions, suspensions, and emulsions.
- These preparations may contain, in addition to the active component, colorants, flavours, stabilisers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilising agents, and the like.
- the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch.
- Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
- Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents.
- Formulations suitable for topical administration in the mouth include lozenges comprising active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
- Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray.
- the formulations may be provided in single or multidose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension.
- the compounds according to the invention may be encapsulated with cyclodextrins, or formulated with other agents expected to enhance delivery and retention in the nasal mucosa.
- Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurised pack with a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
- a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
- CFC chlorofluorocarbon
- the aerosol may conveniently also contain a surfactant such as lecithin.
- a surfactant such as lecithin.
- the dose of drug may be controlled by provision of a metered valve.
- the active ingredients may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
- a powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
- PVP polyvinylpyrrolidone
- the powder carrier will form a gel in the nasal cavity.
- the powder composition may be presented in unit dose form for example in capsules or cartridges of, e. g. gelatin, or blister packs from which the powder may be administered by means of an inhaler.
- the compound In formulations intended for administration to the respiratory tract, including intranasal formulations, the compound will generally have a small particle size for example of the order of 5 to 10 microns or less. Such a particle size may be obtained by means known in the art, for example by micronisation.
- formulations adapted to give sustained release of the active ingredient may be employed.
- the pharmaceutical preparations are preferably in unit dosage forms.
- the preparation is subdivided into unit doses containing appropriate quantities of the active component.
- the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
- the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
- Dosage unit form refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- the specification for the dosage unit forms are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active material for the treatment of a HCV viral infection in living subjects having a diseased condition in which bodily health is impaired.
- the invention also includes the compounds in the absence of carrier where the compounds are in unit dosage form.
- compositions comprising compounds of the invention formulated for oral delivery either alone or in combination with another HCV antiviral agent are particularly preferred.
- the compounds of formula (I) may be used in the treatment of a Flaviviridae viral infection such as a HCV infection.
- the term "treatment" means affecting a subject, tissue or cell to obtain a desired pharmacological and/or physiological effect and includes: (a) inhibiting the viral infection, i.e. arresting its development or further development; (b) relieving or ameliorating the effects of the viral infection, i.e. cause regression of the effects of the viral infection; (c) reducing the incidence or the viral infection or (d) preventing the infection from occurring in a subject, tissue or cell predisposed to the viral infection disease or at risk thereof, but has not yet been diagnosed with a protective pharmacological and/or physiological effect so that the viral infection does not develop or occur in the subject, tissue or cell.
- the prevention of hepatitis C means, for example, administration of a
- subject refers to any animal, in particular mammals such as humans having a disease or condition which requires treatment with the compound of formula (I).
- administering refers to providing the compound or pharmaceutical composition of the invention to a subject suffering from or at risk of the diseases or conditions to be treated or prevented.
- viral infection refers to the introduction of a virus into cells or tissues, e.g., hepatitis C virus (HCV). In general, the introduction of a virus is also associated with replication. Viral infection may be determined by measuring virus antibody titer in samples of a biological fluid, such as blood, using, e.g., enzyme immunoassay. Other suitable diagnostic methods include molecular based techniques, such as RT-PC , direct hybrid capture assay, nucleic acid sequence based amplification, and the like. A virus may infect an organ, e.g., liver, and cause disease, e.g. , hepatitis, cirrhosis, chronic liver disease and hepatocellular carcinoma.
- HCV hepatitis C virus
- Flaviviridae virus refers to a virus of the family Flaviviridae, which family includes the Hepacivirus Flavivirus and Pestivirus or hepatitis C-like virus genera.
- a representative species of the genus of hepatitis C-like viruses is hepatitis C virus.
- terapéuticaally effective amount refers to the amount of the compound of formula (I) that will elicit the biological or medical response of a subject, tissue or cell that is being sought by the researcher, veterinarian, medical doctor or other clinician.
- an appropriate dosage level will generally be about 0.01 to 500 mg per kg subject body weight per day which can be administered in single or multiple doses.
- the dosage level will be about 0.1 to about 250 mg/kg per day; more preferably about 0.5 to about 100 mg/kg per day.
- a suitable dosage level may be about 0.01 to 250 mg/kg per day, about 0.05 to 100 mg/kg per day, or about 0.1 to 50 mg/kg per day. Within this range the dosage may be 0.05 to 0.5, 0.5 to 5 or 5 to 50 mg/kg per day.
- the dosage may be selected, for example to any dose within any of these ranges, for therapeutic efficacy and/or symptomatic adjustment of the dosage to the subject to be treated
- the dosage forms and levels may be formulated for either concurrent, sequential or separate administration or a combination thereof.
- each moiety having a substitutable hydrogen such as for example, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, heterocyclyl, aryl and heteroaryl, in each occurrence as described in the general schemes and methods which follow may be optionally substituted.
- substitutable hydrogen such as for example, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, heterocyclyl, aryl and heteroaryl, in each occurrence as described in the general schemes and methods which follow may be optionally substituted.
- the particular examples which are described herein may undergo further functionalisation using methods known in the art, for example, compounds comprising amino groups or acid groups may undergo reduction amination or amide couplings respectively to form further examples of compounds of the invention.
- compounds of formula (II) are prepared by heating a suitable amino- substituted heterocyclyl with a suitable alpha-halo ketone in the presence of a solvent, such as DMF, and a suitable base, such as potassium carbonate.
- a solvent such as DMF
- a suitable base such as potassium carbonate
- intermediates of formula (II) containing carboxylic ester groups i.e. C0 2 C 1 . 6 alkyl (such as C0 2 CH 3 , C0 2 CH 2 CH 3 and C0 2 CH 2 CH 2 CH 3 ) may be converted to their corresponding carboxylic acids using various conditions (e.g. treatment with aq. NaOH in methanol/THF) which may then be coupled with any suitable primary or secondary amides using a variety of standard peptide coupling techniques to make the corresponding amides (e.g. the use of a peptide coupling agent such as HATU, HBTU, EDCI etc. with the appropriate solvent and base).
- a peptide coupling agent such as HATU, HBTU, EDCI etc.
- a process for producing a compound of formula (I) when B is -CONH-R7- comprising the step of reacting a compound of formula (II) with an amino precursor of general formula NH 2 R 7 under amide coupling conditions.
- Suitable amide coupling conditions will be understood by those skilled in the art and have been described in many references such as Advanced Organic Chemistry - 4 th Edition, March J., John Wiley & Sons Inc, New York, 1992 (see also 5 th Edition, John Wiley & Sons, New York 2001 and 6 th Edition, John Wiley & Sons, New Jersey, 2007).
- compounds of formula (II) have also demonstrated antiviral activity. Accordingly, compounds of formula (II) will be understood to be process intermediates and/or final compounds as the case may be.
- Preparative HPLC was carried out using either a Gilson 322 pump with a Gilson 215 liquid handler and a HP1 100 PDA detector or an Agilent 1200 Series mass detected preparative LCMS using a Varian XRs C-18 100 x 21 .2 mm column. Unless otherwise specified, the HPLC systems employed Phenomenex C8(2) columns using either acetonitrile or acetonitrile containing 0.06% TFA in water or water containing 0.1 % TFA.
- BSA Bovine serum albumin
- DIPEA N,N-Diisopropylethylamine
- DMEM Dulbecco's modified eagle medium
- GTP Guanosine triphosphate
- HATU 2-(7-Aza-1 H-benzotriazole-1 -yl)-1 , 1 ,3,3-tetramethyluronium hexafluorophosphate
- HBTU 0-(Benzotriazol-1 -yl)-/V,/V,/V',A/-tetramethyluronium hexafluorophosphate
- LHMDS Lithium hexamethyldisilazide
- Step a To a solution of 1-(4-fluorophenyl)ethanone (5.00 g; 36.20 mmol) in THF (80 mL) at - 78°C was added a 1 M THF solution of LHMDS in THF (40 mmol). After 30 minutes the cyclohexanone (3.90 g; 40 mmol) in THF (80mL) was added and the reaction mixture was stirred at that temperature for 30 minutes and then quenched upon addition of an aqueous solution of sodium bircarbonate. Ethyl acetate (200 mL) was added and the organic layer was washed with water (2 x 100 mL) then brine (100 mL).
- Step b To a solution of 1-(4-fluorophenyl)-2-(1 -hydroxycyclohexyl)ethanone (350 mg; 1 .48 mmol) in DCM (4 mL) was added triethylsilane (450 mg; 3.90 mmol) followed by TFA (2 mL) and the reaction mixture was stirred for 16 hours at ambient temperature. The reaction mixture was partitioned between EtOAc (75 mL) and water (100 mL). The aqueous layer was extracted with EtOAc (3 x 60 mL) and the combined organics were washed with brine (75 mL), dried (MgS0 4 ) and concentrated to leave a brown oil (4100 mg).
- the crude reaction material was purified by automated flash column chromatography (Biotage-SP4) on silica (80g) eluting with EtOAc and hexane to leave 2-cyclohexyl-1 -(4-fluorophenyl)ethanone (2.20 g) as a colourless oil.
- Step c To a solution of 2-cyclohexyl-1 -(4-fluorophenyl)ethanone (2.50 g; 1 1 .35 mmol) in dioxane/diethyl ether (1 : 1 ; 100 mL) was added bromine (0.64 mL; 12 mmol) and the reaction mixture was stirred at ambient temperature. After 2 hours the reaction mixture was partitioned between EtOAc (125ml) and water (125 ml) and the aqueous layer was separated and extracted with EtOAc (3 x 30 ml). The combined organics were washed with brine (35 mL). dried (MgS0 4 ) and concentrated to leave 2-bromo-2-cyclohexyl-1 -(4- fluorophenyl)ethanone (2.79 g) as a colourless oil.
- Step d To a solution of methyl 5-amino-1 H-pyrazole-3-carboxylate (75 mg; 0.53 mmol) in DMF (2 mL) was added the 2-bromo-2-cyclohexyl-1-(4-fluorophenyl)ethanone ( 170 mg; 0.58 mmol) followed by potassium carbonate (263 mg; 2.66 mmol) and the reaction mixture was stirred at 75°C. After 2 hours water (25 mL) was added and the aqueous layer was extracted with EtOAc (3 x 30 mL). The combined organics were washed with brine (25 mL), dried (MgS0 4 ) and concentrated to leave a brown oil (89 mg).
- Step e To a solution of methyl 3-cyclohexyl-2-(4-fluorophenyl)-1 H-imidazo[1 ,2-b]pyrazole-6- carboxylate (i) (3 mg) in MeOH/THF (1 : 1 ; 1 mL) was added a 1 M aqueous solution of lithium hydroxide (0.09 mmol) and the reaction was heated at 60°C for 3 hrs. A 1 M aqueous solution of citric acid (25 ml) was added and the aqueous layer was extracted with EtOAc (3 x 30 mL). The combined organics were washed with brine (25 mL), dried (MgS0 4 ) and concentrated to leave a brown oil (4 mg). Purification by reverse phase LCMS:
- Step a To a solution of methyl 3-cyclohexyl-2-(4-fluorophenyl)-1 H-imidazo[1 ,2-b]pyrazole-6- carboxylate (i) (10 mg; 0.03 mmol) in DMF (1 mL) was added iodomethane (0.06 mmol) followed by potassium carbonate (29 mg; 0.29 mmol). After 16 hours H 2 0 (25 ml) was added and the aqueous layer was extracted with EtOAc (3 x 30 mL). The combined organics were washed with brine (25 mL), dried (MgS0 4 ) and concentrated to leave a brown oil (12 mg).
- Step b To a solution of methyl 3-cyclohexyl-2-(4-fluorophenyl)-1 -methyl-imidazo[1 ,2- b]pyrazole-6-carboxylate (iii) (5 mg; 0.01 mmol) in MeOH/THF (1 : 1 ; 2 mL) was added a 1 M aqueous solution of lithium hydroxide (0.1 mmol). The reaction was heated at 60°C for 2 hrs.
- Step a To a solution of ethyl 5-amino-1 H-pyrazole-4-carboxylate (30 mg; 0.19 mmol) in DMF (2 ml_) was added 2-bromo-2-cyclohexyl-1-(4-fluorophenyl)ethanone (64 mg; 0.21 mmol) followed by potassium carbonate (96 mg; 0.97 mmol) and the reaction was stirred at ambient temperature for 4 hours. H 2 0 (25 ml) was added and the aqueous layer was extracted with EtOAc (3 x 30 ml_) and the combined organics were washed with brine (25 ml_), dried (MgS0 4 ) and concentrated to leave a brown oil (85 mg).
- Step b To a solution of ethyl 3-cyclohexyl-2-(4-fluorophenyl)-1 H-imidazo[1 ,2-b]pyrazole-7- carboxylate (v) (75 mg; 0.21 mmol) in DMF (5 mL) was added iodomethane (60 mg; 0.42 mmol) followed by potassium carbonate (105 mg; 1 .06 mmol). After 16 hours H 2 0 (25 ml) was added and the aqueous layer was extracted with EtOAc (3 x 30 mL). The combined organics were washed with brine (25 mL), dried (MgS0 4 ) and concentrated to leave a brown oil (65 mg).
- Step c To a solution of ethyl 3-cyclohexyl-2-(4-fluorophenyl)-1 -methyl-imidazo[1 ,2- b]pyrazole-7-carboxylate (vi) (20 mg; 0.05 mmol) in MeOH/THF (1 :1 ; 2 mL) was added a 1 M aqueous solution of lithium hydroxide (1 .08 mmol). The reaction was heated at 60 °C for 6 hrs. 1 M HCI was added until ⁇ pH 3 and the aqueous layer was extracted with EtOAc (3 x 30 mL). The combined organics were washed with brine (25 mL), dried (MgS0 4 ) and concentrated to leave a brown oil (15 mg). Purification by reverse phase LCMS:
- Step a A 1 M solution of zinc chloride in diethyl ether (39.5 mL) was added to 140 mL anhydrous ether under an atmosphere of argon at 0°C. To this was added
- Step b To a solution of 2-cyclohexyl-1-phenylethanone (3470 mg) in dioxane/diethyl ether (1 : 1 , 20 mL) was added at rt bromine (930 ⁇ _) in portions over 40 min (progress monitored by 1 H NMR), and the brown mixture was stirred at ambient temperature for another 30 min. Work-up: the reaction mixture was partitioned between EtOAc (100 ml) and NaHC0 3 (100 ml). The aqueous layer was separated and extracted with EtOAc (100 ml).
- Step c To a solution of ethyl 5-amino-1 /-/-pyrazole-4-carboxylate (120 mg) in anhydrous DMF (5 mL) was added under an atmosphere of argon 2-bromo-2-cyclohexyl-1 - phenylethanone (185 mg) followed by potassium carbonate (320 mg), and the reaction mixture was stirred at 100 °C for 2 hrs and at rt for 17 hrs. After this period iodomethane (50 pL) was added and the reaction mixture was stirred at rt for 20 min.
- Step d A solution of ethyl 3-cyclohexyl-1 -methyl-2-phenyl-1 H-imidazo[1 ,2-b]pyrazole-7- carboxylate (ix) (60 mg) in 1 M aquous KOH/1 ,4-dioxane (6.4 mL, 1 : 1 ) was heated at reflux for 2 hrs. The reaction mixture was cooled to 0°C, and adjusted to pH 7 with 1 M HCI and satd NaHC0 3 solution, extracted with EtOAc (2x 20 mL), the combined organic layers were washed with brine (10 mL), dried (MgS0 4 ), filtered and evaporated to drynes to afford an oil that solidified on standing.
- Step a To a mixture of 63 mL water, 7 mL 7 N NaOH and 60 mL 1 ,2-dichloroethane was added 1 -(2-hydroxyphenyl)ethanone, 1 100 mg tetrabutylammonium bromide and 1 -bromo-2- chloroethane (4.5 mL), and the reaction mixture was stirred vigorously at rt for 96 hrs, then heated at reflux for 16 hrs.
- Step b To a solution of 1-[2-(2-chloroethoxy)phenyl]ethanone (4200 mg) in THF (90 mL) at - 78 C was added under an atmosphere of argon a 1 M THF solution of LiHMDS (25 mL). After 30 minutes cyclohexanone (2520 ⁇ ) in THF (10 mL) was added and the reaction mixture was stirred at -78 °C for 1 .5 hrs.
- Step c To a solution of 1-[2-(2-chloroethoxy)phenyl]-2-(1 -hydroxycyclohexyl)ethanone (4910 mg) in anhydrous dichloromethane (100 mL, argon) was added under an atmosphere of argon triethylsilane (27 mL) followed by trifluoroacetic acid (1.5 mL) and the reaction mixture was stirred at ambient temperature for 2.5 days. Progress of the reaction was monitored by TLC. After ca 90% conversion to the product, the reaction mixture was quenched with satd. NaHC0 3 solution (100 mL), followed by extraction with DCM (2x50 mL). The combined organic layers were dried (MgS0 4 ), filtered and evaporated to dryness.
- Step d To a solution of 1-[2-(2-chloroethoxy)phenyl]-2-cyclohexylethanone (1000 mg) in dioxane/diethyl ether (1 : 1 , 60 mL) was added bromine (180 pL), and the brown mixture was stirred at ambient temperature for 30 min. The progress of the reaction was followed by LCMS. After 30 min reaction time, more bromine (9 pL) was added and stirring was continued for 30 min. The reaction mixture was partitioned between EtOAc (150 ml) and NaHC0 3 (50 ml). The aqueous layer was separated and extracted with EtOAc (50 ml).
- Step e To a solution of methyl 5-amino-1 H-pyrazole-3-carboxylate hydrochloride (270 mg) in anhydrous DMF (18 mL) under an atmosphere of argon was added sodium hydride (60% in mineral oil, 130 mg) at 0 °C. The reaction mixture was stirred at this temperature for 45 min followed by addition of a solution of 2-bromo-1 -[2-(2-chloroethoxy)phenyl]-2- cyclohexylethanone (500 mg) in anhydrous DMF (18 mL). The reaction mixture was stirred at rt for 21 hrs, followed by heating at 100 °C for 1 hr. The progress of the reaction was monitored by LCMS.
- Reaction mixture was acidified with glacial acetic acid, concentrated on the rotavap (60 °C), the residue was partitioned between water and EtOAc (200 mL, 1 : 1 ), the aqueous layer was extracted with EtOAc (100 mL), the combined organic layers were dried (MgS0 4 ), filtered and evaporated to dryness to leave a brown oil.
- Step f A solution of methyl 13-cyclohexyl-6,7-dihydropyrazolo[5',1':2,3]imidazo[1,5- c][1,4]benzoxazepine-10-carboxylate (xi) (40 mg) in 1M aquous KOH/1 ,4-dioxane (6 mL, 1:1) was heated at reflux for 15 min. Reaction mixture was cooled to 0°C, and adjusted to pH 5 with 1 M HCI, then extracted with EtOAc (2x 20 mL), the combined organic layers were washed with brine (10 mL), dried (MgS0 4 ), filtered and evaporated to dryness: 31.3 mg (81 % yield) oil.
- Step a Resorcinol (2370 mg) and boron trifluoride etherate (4.50 mL) were combined in a RBF under an atmosphere of argon (suspension) and stirred at rt. Cyclohexylacetyl chloride (3.00 mL) was added over a period of 30 min and the reaction mixture was stirred at rt o/n. The reaction mixture was added dropwise to 200 mL 10% aqueous NaOAc solution, stirred at rt for 30 min, then extracted into ether (2x100 mL). The combined organic layers were dried (MgS0 4 ), filtered and evaporated to dryness.
- Step b To a solution of 2-cyclohexyl-1-(2,4-dihydroxyphenyl)ethanone in anhydrous acetonitrile (100 mL) was added under an atmosphere of argon potassium carbonate (4.20 g) and benzyl bromide ( 2.40 mL) and the reaction mixture was stirred at rt for 17 hrs. After this period diethyl ether (300 mL) was added and the mixture was filtered. The filter cake was washed with diethyl ether, and the filtrate was evaporated to dryness to afford 6.15 g of a colourless solid.
- Step c To a solution of 1-[4-(benzyloxy)-2-hydroxyphenyl]-2-cyclohexylethanone (3000 mg) in 1 ,2-dichloroethane (70 mL) was added 1-bromo-2-chloroethane (1200 ⁇ ),
- Step d To a solution of 1-[4-(benzyloxy)-2-(2-chloroethoxy)phenyl]-2-cyclohexylethanone (2850 mg) in dioxane/diethyl ether (1 : 1 , 160 mL) was added bromine (450 ⁇ ) dropwise within 2 min, and the mixture was stirred at ambient temperature. The reaction was monitored by LCMS. More bromine (2 x 10 ⁇ ) was added in 10 min intervals to reach complete conversion of 1-[4-(benzyloxy)-2-(2-chloroethoxy)phenyl]-2-cyclohexylethanone.
- Step e To a solution of methyl 5-amino-1 A7-pyrazole-3-carboxylate hydrochloride (350 mg) in anhydrous DMF (15 ml_) was added under an atmosphere of argon sodium hydride (60% in mineral oil, 175 mg) at 0 °C. The reaction mixture was stirred at this temperature for 20 min followed by addition of a solution of 1-[4-(benzyloxy)-2-(2-chloroethoxy)phenyl]-2-bromo- 2-cyclohexylethanone (810 mg) in anhydrous DMF (30 ml_). The progress of the reaction was monitored by LCMS.
- reaction mixture was stirred at rt for 17 hrs, then heated at 100 °C for 1 hr. After this period the reaction mixture was cooled to rt, acidified with glacial acetic acid and concentrated on the rotavap (60 °C). The residue was partitioned between water and EtOAc (100 ml_, 1 : 1 ), the aqueous layer was extracted with EtOAc (50 mL), the combined organic layers were washed with brine (20 mL), dried (MgS0 4 ), filtered and evaporated to dryness to leave a brown oil.
- Step f To a solution of methyl 3-(benzyloxy)-13-cyclohexyl-6,7- dihydropyrazolo[5',1 ':2,3]imidazo[1 ,5-c/][1 ,4]benzoxazepine-10-carboxylate (xiii) (15 mg) in methanol (12 ml_) was added palladium on carbon (10%, 3 mg) and the mixture was stirred under a hydrogen atmosphere (4 L gasbag) for 65 min. Work-up: reaction mixture was flushed with argon and filtered through filter aid (Hiflo medium) with methanol. The filtrate was evaporated to dryness.
- Step a To a solution of (xiv) (10 mg) in anhydrous DMF (1 mL) was added at 0 °C and under under an atmosphere of argon NaH (1 .3 mg). The mixture was stirred at this temperature for 30 min. A solution of 1-[3-(chloromethyl)-4-(morpholin-4-yl)phenyl]pyrrolidin-
- Step b A solution of (xviii) (6 mg) in 1 M aqueous KOH/1 ,4-dioxane (3 mL, 1 : 1 ) was heated at 40 °C for 30 min, then stirred at rt for 2 hrs. The reaction mixture was cooled to 0°C, and adjusted to pH 5 with 1 M HCI, and extracted with EtOAc (2x 10 mL). The combined organic layers were washed with brine (5 mL), dried (MgS0 4 ), filtered and evaporated to dryness to afford a solid. The crude material was purified on reverse phase silica by gradient elution (C18; 0-100% acetonitrile/H 2 0) and freeze-dried to afford 2.5 mg (43% yield) 13-cyclohexyl-
- Step a To a solution of 3-cyclohexyl-2-(4-fluorophenyl)-1 -methyl-imidazo[1 ,2-b]pyrazole-6- carboxylic acid (iv) (5.0 mg; 0.01 mmol) in DMF (1 mL) at ambient temperature was added ethyl (2E)-3-(4- ⁇ [(1 -aminocyclobutyl)carbonyl] amino ⁇ phenyl)prop-2-enoate hydrochloride (0.02 mmol) followed by HATU (16.7 mg; 0.04 mmol) and DIPEA (5.7 mg; 0.04 mmol).
- Step b To a solution of ethyl (E)-3-[4-[[1-[[3-cyclohexyl-2-(4-fluorophenyl)-1 -methyl- imidazo[1 ,2-b]pyrazole-6-carbonyl]amino]cyclobutanecarbonyl]amino] phenyl]prop-2-enoate (1 ) (4 mg; 0.007 mmol) in MeOH/THF (1 : 1 ; 2 mL) was added a 1 M aqueous solution of lithium hydroxide (0.14 mmol) and the reaction mixture was heated at 60°C for 2 hrs.
- Step a To a solution of 3-cyclohexyl-2-(4-fluorophenyl)-1 -methyl-imidazo[1 ,2-b]pyrazole-7- carboxylic acid (vii) (3 mg; 0.01 mmol) in DCM (1 mL) was added ethyl (E)-3-[4-[(1- aminocyclobutanecarbonyl)amino]phenyl]prop-2-enoate (3.8 mg; 0.01 mmol) followed by HATU (10 mg; 0.03 mmol) and DIPEA (3.4 mg; 0.03 mmol).
- Step b To a solution of ethyl (E)-3-[4-[[1-[[3-cyclohexyl-2-(4-fluorophenyl)-1 -methyl- imidazo[1 ,2-b]pyrazole-7-carbonyl]amino]cyclobutanecarbonyl] amino]phenyl]prop-2-enoate (4) (5 mg; 0.01 mmol) in MeOH/THF (1 : 1 ; 2 mL) was added a 1 M aqueous solution of lithium hydroxide (0.16 mmol) and the reaction was heated at 60°C for 3 hrs.
- Step a To a solution of compound 3-cyclohexyl-1 -methyl-2-phenyl-1 H-imidazo[1 ,2- 6]pyrazole-7-carboxylic acid (x) (10 mg) and ethyl (2E)-3-(4- ⁇ [(1- aminocyclobutyl)carbonyl]amino ⁇ phenyl)prop-2-enoate hydrochloride (15 mg) in dry DMF (500 was added under an atmosphere of argon DIPEA (20 pL) followed by HATU (17.6 mg). The reaction mixture was stirred at rt for 16 hrs. Work-up: EtOAc (15 mL) was added and this mixture was washed with brine (5 mL) and concentrated.
- Step b A suspension of compound (6) (4.5 mg) in 1 ,4-dioxane/isopropanol/0.6 M aqueous LiOH (0.1 mL/0.1 mL/0.08 mL) was stirred at 60-85 °C for 35 min. Work-up: the reaction mixture was cooled in ice/water, acidified with 1 M HCI and concentrated.
- Step a To a solution of 13-cyclohexyl-6J-dihydropyrazolo[5',1':2,3]imidazo[1 ,5- c][1,4]benzoxazepine-10-carboxylic acid (xii) (10 mg) and ethyl 1- aminocyclobutanecarboxylate hydrochloride (5.7 mg) in dry DMF (2 mL) under an atmosphere of argon was added DIPEA (16 pL) followed by HATU (13 mg). The reaction mixture was stirred at rt for 17 hrs.
- Step b A solution of compound (8) (9 mg) in 1 M aquous KOH/1 ,4-dioxane (6 mL, 1 : 1 ) was heated at reflux for 15 min, cooled to 0°C, and adjusted to pH 5 with 1 M HCI and evaporated to dryness.
- Step c To a solution of compound (9) (7 mg) and ethyl (2E)-3-(4-aminophenyl)prop-2- enoate (3.5 mg) in dry DMF (2 mL) under under an atmosphere of argon was added DIPEA (10 pL) followed by HATU (7.5 mg). The reaction mixture was stirred at rt for 20 hrs. Workup: EtOAc (15 mL) was added and the mixture was washed with brine (5 mL), dried (MgS0 4 ), filtered and concentrated.
- Step d A suspension of 9 mg compound (10) in 1 ,4-dioxane/isopropanol/0.5 M aqueous LiOH (0.4 mL/0.4 mL/0.32 mL) was stirred in a flask under an atmosphere of argon at 65 °C for 60 min. Work-up: reaction mixture was cooled in ice/water, acidified with 1 M HCI (pH 5) and concentrated.
- Step a To a solution of 3-cyclohexyl-2-(4-fluorophenyl)-1-methyl-imidazo[1,2-b]pyrazole-6- carboxylic acid (iv) (15 mg; 0.04 mmol) in DCM (1 mL) at ambient temperature was added methyl (2S)-2-amino-3-(4-hydroxyphenyl)propanoate hydrochloride (15 mg; 0.07 mmol), HATU (50 mg; 0.13 mmol) and DIPEA (17 mg; 0.13mmol). After 16 hours a saturated aqueous solution of NaHC0 3 (15 ml) was added and the aqueous layer was extracted with EtOAc (3x 15 mL).
- Step b To a solution of crude methyl (2S)-2-[[3-cyclohexyl-2-(4-fluorophenyl)-1-methyl- imidazo[1,2-b]pyrazole-6-carbonyl]amino]-3-(4-hydroxyphenyl)propanoate (12) (8 mg) in MeOH/THF (1:1; 2 mL) was added a 1M aqueous solution of lithium hydroxide (0.31 mmol) and the reaction was heated at 60°C for 2 hrs.1M HCI ( aq) was added until ⁇ pH3 and the aqueous layer was extracted with EtOAc (3x 15 mL) and the combined organics were washed with brine (15 mL), dried (MgS0 4 ) and concentrated to leave a brown oil (3 mg).
- Step a To a solution of 3-cyclohexyl-2-(4-fluorophenyl)-1-methyl-imidazo[1 ,2-b]pyrazole-6- carboxylic acid (iv) (15 mg; 0.04 mmol) in DCM (1 mL) was added methyl (2S)-2-amino-3- (1H-indol-3-yl)propanoate hydrochloride (17 mg; 0.07 mmol) followed by HATU (33 mg; 0.09 mmol) and DIPEA (23 mg; 0.18 mmol). After 2 hours a saturated aqueous solution of NaHC0 3 (15 ml) was added and the aqueous layer was extracted with EtOAc (3x15 mL). The combined organics were washed with brine (10 mL), dried (MgS0 4 ) and concentrated to leave a brown oil (17 mg). Purification of a 4 mg portion by reverse phase LCMS:
- Step b To a solution of crude methyl N- ⁇ [3-cyclohexyl-2-(4-fluorophenyl)-1-methyl-1H- imidazo[1,2-b]pyrazol-6-yl]carbonyl ⁇ -L-tryptophanate (14) (10 mg) in MeOH/THF (1:1; 2mL) was added a 1M aqueous solution of lithium hydroxide (0.37 mmol).
- the in vitro and in vivo antiviral activity of the compounds of the invention may be determined using the following protocols.
- HCV polymerase reactions were carried out using a modified method of Howe et ai , Antimicrobial Agents and Chemotherapy 2004 48(12): 4813-4821.
- Reactions contained 50 nM NS5bA21 , 20 mM Tris-HCI pH 7.5, 5 rtiM MgCI 2 , 5 mM MnCI 2 , 3 mM DTT, 0.05% BSA, 0.2 U/pL RNasin, 10 ⁇ g mL Poly(rC) template, GTP (at Km) and 0.05 pCi/pL 33 P-GTP in a total reaction volume of 50 pL.
- a genotype 1 b subgenomic replicon cell line based on Blight et al., Science 2000 290: 1972-1974, modified to express a Renilla luciferase reporter gene was used to assess antiviral activity of test compounds.
- Cell cultures were maintained in a sub-confluent state in DMEM with glutamine, 10% heat-inactivated foetal bovine serum and Geneticin.
- Table 2 provides EC 50 values for selected carboxylic esters of the invention.
- Table 2 EC 50 and IC 50 values for selected compounds of the invention
- Cytotoxicity of compounds against genotype 1 b subgenomic replicon cells were assessed using the MTT assay (Watanabe et al. , Journal of Virological Methods 1994 48:257-265). Plates were prepared as described for the HCV eplicon assay and cytotoxicity of the test article was evaluated after three days. MTT was added to assay plates followed by three hour incubation at 37 ° C. Wells were aspirated to dryness and the formazan dye dissolved by the addition of 100% isopropanol. Absorbencies were read in a spectrophotometer at two wavelengths (540 nm and 690 nm). The compound concentration that reduced cell viability by 50% (CC 50 ) is calculated using non-linear regression.
- HCV replicon assays and HCV polymerase assays for genotypes 1 b, 1 a, 2a and 3a to determine the cross-genotype HCV activity of a compound are conducted using essentially the same methods as described above.
- a genotype 1 b (Con 1 ) subgenomic replicon cell line based on Blight et al. , Science 2000 290: 1972-1974, modified to express a Renilla luciferase reporter gene is used to assess synergy of test compounds.
- Cell cultures were maintained in a sub-confluent state in DMEM with glutamine, 10% heat-inactivated foetal bovine serum (FBS) and G418 (Geneticin®).
- Results are analysed and levels of synergy assessed via generation of 3D synergy plots using MacSynergyTM II (Prichard, M. N., K. R. Aseltine, and C. Shipman, Jr. 1993. MacSynergy II. Version 1.0. User's manual. University of Michigan, Ann Arbor.).
- This method is therefore useful in determining synergistic combinations of an inhibitor of the invention and an HCV inhibitor targeting a different viral protein, or with a different mechanism of inhibiting the NS5B polymerase (for example an NS5A inhibitor, a nucleoside or nucleotide NS5B inhibitor or a NS3/4A protease inhibitor)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des inhibiteurs des polymérases virales de formule (I), de leurs sels, solvats, hydrates, racémates, énantiomères et isomères, en particulier des inhibiteurs des polymérases virales au sein de la famille des Flaviviridae comme le virus de l'hépatite C (VHC), des procédés pour leur préparation et leur utilisation dans le traitement d'infections virales par Flaviviridae comme les infections par le virus de l'hépatite C (VHC).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161535666P | 2011-09-16 | 2011-09-16 | |
US61/535,666 | 2011-09-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013036994A1 true WO2013036994A1 (fr) | 2013-03-21 |
Family
ID=47882443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2012/001091 WO2013036994A1 (fr) | 2011-09-16 | 2012-09-13 | Composés pour le traitement des infections par vhc |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2013036994A1 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9717731B2 (en) | 2012-11-02 | 2017-08-01 | Pharmacyclics Llc | TEC family kinase inhibitor adjuvant therapy |
US9814721B2 (en) | 2010-06-03 | 2017-11-14 | Pharmacyclics Llc | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
US10316040B2 (en) | 2015-10-16 | 2019-06-11 | Eisai R&D Management Co., Ltd. | EP4 antagonists |
US10954567B2 (en) | 2012-07-24 | 2021-03-23 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK) |
CN113039186A (zh) * | 2018-11-02 | 2021-06-25 | 艾库里斯有限及两合公司 | 抗乙型肝炎病毒HBV的脲6,7-二氢-4H-吡唑并[1,5-a]吡嗪活性剂 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008141385A1 (fr) * | 2007-05-21 | 2008-11-27 | Biota Scientific Management Pty Ltd | Inhibiteurs de polymérases virales |
-
2012
- 2012-09-13 WO PCT/AU2012/001091 patent/WO2013036994A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008141385A1 (fr) * | 2007-05-21 | 2008-11-27 | Biota Scientific Management Pty Ltd | Inhibiteurs de polymérases virales |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10653696B2 (en) | 2010-06-03 | 2020-05-19 | Pharmacyclics Llc | Use of inhibitors of bruton's tyrosine kinase (BTK) |
US10751342B2 (en) | 2010-06-03 | 2020-08-25 | Pharmacyclics Llc | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
US11672803B2 (en) | 2010-06-03 | 2023-06-13 | Pharmacyclics Llc | Use of inhibitors of Brutons tyrosine kinase (Btk) |
US10004745B2 (en) | 2010-06-03 | 2018-06-26 | Pharmacyclics Llc | Use of inhibitors of Bruton'S tyrosine kinase (Btk) |
US10004746B2 (en) | 2010-06-03 | 2018-06-26 | Pharmacyclics Llc | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
US10016435B2 (en) | 2010-06-03 | 2018-07-10 | Pharmacyclics Llc | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
US9814721B2 (en) | 2010-06-03 | 2017-11-14 | Pharmacyclics Llc | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
US10478439B2 (en) | 2010-06-03 | 2019-11-19 | Pharmacyclics Llc | Use of inhibitors of bruton's tyrosine kinase (Btk) |
US10954567B2 (en) | 2012-07-24 | 2021-03-23 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK) |
US9717731B2 (en) | 2012-11-02 | 2017-08-01 | Pharmacyclics Llc | TEC family kinase inhibitor adjuvant therapy |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
US10316040B2 (en) | 2015-10-16 | 2019-06-11 | Eisai R&D Management Co., Ltd. | EP4 antagonists |
US10941148B2 (en) | 2015-10-16 | 2021-03-09 | Eisai R&D Management Co., Ltd. | EP4 antagonists |
US11434246B2 (en) | 2015-10-16 | 2022-09-06 | Eisai R&D Management Co., Ltd. | EP4 antagonists |
CN113039186A (zh) * | 2018-11-02 | 2021-06-25 | 艾库里斯有限及两合公司 | 抗乙型肝炎病毒HBV的脲6,7-二氢-4H-吡唑并[1,5-a]吡嗪活性剂 |
JP2022512870A (ja) * | 2018-11-02 | 2022-02-07 | アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | B型肝炎ウイルス(hbv)に対して活性を有する新規尿素6,7-ジヒドロ-4h-ピラゾロ[1,5-a]ピラジン |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105001225B (zh) | 脂质合成的杂环调节剂 | |
WO2011153588A1 (fr) | Inhibiteurs de polymérase virale | |
EP4001279A1 (fr) | Nouveaux agents antiviraux dérivés de spiropyrrolidine | |
AU2014234906B2 (en) | Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors | |
EP3860989B1 (fr) | Pyrrolines fusionnées qui agissent en tant qu'inhibiteurs de la protéase 30 (usp30) spécifique de l'ubiquitine | |
WO2013036994A1 (fr) | Composés pour le traitement des infections par vhc | |
AU2015339196A1 (en) | Substituted tetrahydropyrans and method of use | |
WO2016174079A1 (fr) | Composés de pyrazolo- et triazolo-pyrimidine antiviraux du virus respiratoire syncytial (vrs) | |
WO2008141385A1 (fr) | Inhibiteurs de polymérases virales | |
CN116139138A (zh) | 脂质合成的杂环调节剂 | |
US8546389B2 (en) | Viral polymerase inhibitors | |
WO2017156165A1 (fr) | Inhibiteurs de la 3-phosphoglycérate déshydrogénase et leurs utilisations | |
WO2023003610A1 (fr) | Nouveaux agents antiviraux dérivés de spiropyrrolidine | |
US8785478B2 (en) | Viral polymerase inhibitors | |
CN114262322A (zh) | 一类细胞程序性坏死抑制剂及其制备方法和用途 | |
KR20230142706A (ko) | 옥시토신 수용체 조절제 | |
CN106008552B (zh) | 苯并[e]吡唑并[1,5-c][1,3]噁嗪类化合物及其应用 | |
WO2013075173A1 (fr) | Composés destinés à traiter le vhc | |
WO2021253098A1 (fr) | Composés amido | |
CN105985355B (zh) | 稠合三环类肝炎病毒抑制剂及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12832384 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12832384 Country of ref document: EP Kind code of ref document: A1 |